Cover Page
Cover Page - shares | 3 Months Ended | |
Mar. 31, 2023 | Apr. 24, 2023 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Mar. 31, 2023 | |
Document Transition Report | false | |
Entity File Number | 0-19311 | |
Entity Registrant Name | BIOGEN INC. | |
Entity Central Index Key | 0000875045 | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Year Focus | 2023 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | false | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 33-0112644 | |
Entity Address, Address Line One | 225 Binney Street | |
Entity Address, City or Town | Cambridge | |
Entity Address, State or Province | MA | |
Entity Address, Postal Zip Code | 02142 | |
City Area Code | 617 | |
Local Phone Number | 679-2000 | |
Title of 12(b) Security | Common Stock, $0.0005 par value | |
Trading Symbol | BIIB | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 144,742,305 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Millions | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Total revenue | $ 2,463 | $ 2,531.8 |
Cost and expenses: | ||
Cost of sales, excluding amortization and impairment of acquired intangible assets | 662.8 | 753.9 |
Research and development | 570.6 | 551.7 |
Selling, general and administrative | 605 | 634.9 |
Amortization and impairment of acquired intangible assets | 50.2 | 66.9 |
Collaboration profit sharing/(loss reimbursement) | 57.1 | (117.3) |
(Gain) loss on fair value remeasurement of contingent consideration | 0 | (7.1) |
Restructuring charges | 9.6 | 38.1 |
Other (income) expense, net | 69.4 | 263.3 |
Total cost and expense | 2,024.7 | 2,184.4 |
Income before income tax expense and equity in loss of investee, net of tax | 438.3 | 347.4 |
Income tax (benefit) expense | 50.7 | 125.6 |
Equity in (income) loss of investee, net of tax | 0 | 3.3 |
Net income | 387.6 | 218.5 |
Net income (loss) attributable to noncontrolling interests, net of tax | (0.3) | (85.3) |
Net income attributable to Biogen Inc. | $ 387.9 | $ 303.8 |
Net income per share: | ||
Basic earnings per share attributable to Biogen Inc. | $ 2.69 | $ 2.06 |
Diluted earnings per share attributable to Biogen Inc. | $ 2.67 | $ 2.06 |
Weighted-average shares used in calculating: | ||
Basic earnings per share attributable to Biogen Inc. | 144,400 | 147,100 |
Diluted earnings per share attributable to Biogen Inc. | 145,200 | 147,600 |
Product, net | ||
Total revenue | $ 1,763.3 | $ 2,066.3 |
LEQEMBI Collaboration | ||
Total revenue | (18.9) | 0 |
Revenue from anti-CD20 therapeutic programs | ||
Total revenue | 399.5 | 399.4 |
Contract manufacturing, royalty and other revenue | ||
Total revenue | $ 319.1 | $ 66.1 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Statement of Comprehensive Income [Abstract] | ||
Net income attributable to Biogen Inc. | $ 387.9 | $ 303.8 |
Other comprehensive income: | ||
Unrealized gains (losses) on securities available for sale, net of tax | 5.7 | (9.7) |
Unrealized gains (losses) on cash flow hedges, net of tax | (35.4) | 15.9 |
Gains (losses) on net investment hedges, net of tax | 0 | 6.2 |
Unrealized gains (losses) on pension benefit obligation, net of tax | 0.5 | 0.9 |
Currency translation adjustment | 22.1 | (21.8) |
Total other comprehensive income (loss), net of tax | (7.1) | (8.5) |
Comprehensive income (loss) attributable to Biogen Inc. | 380.8 | 295.3 |
Comprehensive income (loss) attributable to noncontrolling interests, net of tax | (0.3) | (85.3) |
Comprehensive income (loss) attributable to noncontrolling interests, net of tax | $ 380.5 | $ 210 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions | Mar. 31, 2023 | Dec. 31, 2022 |
Current assets: | ||
Cash and cash equivalents | $ 2,898.2 | $ 3,419.3 |
Marketable securities | 2,143.1 | 1,473.5 |
Accounts receivable, net | 1,634.4 | 1,705 |
Due from anti-CD20 therapeutic programs | 393.8 | 431.4 |
Inventory | 1,281 | 1,344.4 |
Other current assets | 1,412 | 1,417.6 |
Total current assets | 9,762.5 | 9,791.2 |
Marketable securities | 978.2 | 705.7 |
Property, plant and equipment, net | 3,300.9 | 3,298.6 |
Operating lease assets | 399.1 | 403.9 |
Intangible assets, net | 1,813.3 | 1,850.1 |
Goodwill | 5,751.8 | 5,749 |
Deferred tax asset | 1,211.8 | 1,226.4 |
Investments and other assets | 1,380.8 | 1,529.2 |
Total assets | 24,598.4 | 24,554.1 |
Current liabilities: | ||
Taxes payable | 235.5 | 259.9 |
Accounts payable | 491.2 | 491.5 |
Accrued expense and other | 2,288.2 | 2,521.4 |
Total current liabilities | 3,014.9 | 3,272.8 |
Notes payable | 6,282.7 | 6,281 |
Deferred tax liability | 251.3 | 334.7 |
Long-term operating lease liabilities | 327 | 333 |
Other long-term liabilities | 935.5 | 944.2 |
Total liabilities | 10,811.4 | 11,165.7 |
Commitments, contingencies and guarantees | ||
Biogen Idec Inc. shareholders' equity | ||
Preferred stock, par value $0.001 per share | 0 | 0 |
Common stock, par value $0.0005 per share | 0.1 | 0.1 |
Additional paid-in capital | 91.2 | 73.3 |
Accumulated other comprehensive income (loss) | (172) | (164.9) |
Retained earnings | 16,854.4 | 16,466.5 |
Treasury stock, at cost | (2,977.1) | (2,977.1) |
Total Biogen Inc. shareholders’ equity | 13,796.6 | 13,397.9 |
Noncontrolling interests | (9.6) | (9.5) |
Total equity | 13,787 | 13,388.4 |
Total liabilities and equity | $ 24,598.4 | $ 24,554.1 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Cash flow from operating activities: | ||
Net income | $ 387.6 | $ 218.5 |
Adjustments to reconcile net income to net cash flow from operating activities: | ||
Depreciation and amortization | 112.3 | 143.1 |
Excess and obsolescence charges related to inventory | 17.4 | 281.5 |
Share-based compensation | 75.6 | 67.6 |
Contingent consideration | 0 | (7.1) |
Deferred income taxes | (64.5) | 1 |
(Gain) loss on strategic investments | 79.6 | 191.1 |
(Gain) loss on equity method investments | 0 | 3.3 |
Other | 31.4 | 43.3 |
Changes in operating assets and liabilities, net: | ||
Accounts receivable | 77.2 | (87.5) |
Due from anti-CD20 therapeutic programs | 37.6 | 22.9 |
Inventory | 27.9 | (142.6) |
Accrued expense and other current liabilities | (295) | (461.6) |
Income tax assets and liabilities | 65 | 101.9 |
Other changes in operating assets and liabilities, net | (96.8) | (213.6) |
Net cash flow provided by (used in) operating activities | 455.3 | 161.8 |
Cash flows from investing activities: | ||
Purchases of property, plant and equipment | (66.6) | (57.9) |
Proceeds from sales and maturities of marketable securities | 406.7 | 543.6 |
Purchases of marketable securities | (1,321.2) | (1,133.5) |
Acquisitions of intangible assets | (5) | 0 |
Proceeds from sales of strategic investments | 33.8 | 0 |
Other | (0.7) | (0.2) |
Net cash flow provided by (used in) investing activities | (953) | (648) |
Cash flows from financing activities: | ||
Payments related to issuance of stock for share-based compensation arrangements, net | (60.1) | (20.8) |
Net (distribution) contribution to noncontrolling interest | 0.2 | 0.2 |
Other | 16.5 | 4.1 |
Net cash flow provided by (used in) financing activities | (43.4) | (16.5) |
Net increase (decrease) in cash and cash equivalents | (541.1) | (502.7) |
Effect of exchange rate changes on cash and cash equivalents | 20 | (9.4) |
Cash and cash equivalents, beginning of the period | 3,419.3 | 2,261.4 |
Cash and cash equivalents, end of the period | $ 2,898.2 | $ 1,749.3 |
Condensed Consolidated Statem_4
Condensed Consolidated Statement of Equity Statement - USD ($) shares in Millions, $ in Millions | Total | Preferred stock | Common stock | Additional paid-in capital | Accumulated Other Comprehensive Income | Retained earnings | Treasury stock | Parent | Noncontrolling interest |
Beginning balance, shares at Dec. 31, 2021 | 0 | 170.8 | 23.8 | ||||||
Beginning balance at Dec. 31, 2021 | $ 10,959.7 | $ 0 | $ 0.1 | $ 68.2 | $ (106.7) | $ 13,911.7 | $ (2,977.1) | $ 10,896.2 | $ 63.5 |
Net income | 218.5 | 303.8 | 303.8 | (85.3) | |||||
Other comprehensive income (loss), net of tax | (8.5) | (8.5) | (8.5) | ||||||
Capital contribution from noncontrolling interest | 0.2 | 0.2 | |||||||
Issuance of common stock under stock option and stock purchase plans, shares | 0.1 | ||||||||
Issuance of common stock under stock option and stock purchase plans | 18.9 | 18.9 | 18.9 | ||||||
Issuance of common stock under award plan, shares | 0.4 | ||||||||
Issuance of common stock under stock award plan | (39.7) | (39.7) | 0 | (39.7) | |||||
Compensation related to share-based payments | 70.4 | 70.4 | 70.4 | ||||||
Other | 1.2 | 1.2 | 1.2 | ||||||
Ending balance at Mar. 31, 2022 | 11,220.7 | $ 0 | $ 0.1 | 119 | (115.2) | 14,215.5 | $ (2,977.1) | 11,242.3 | (21.6) |
Ending balance, shares at Mar. 31, 2022 | 0 | 171.3 | 23.8 | ||||||
Beginning balance, shares at Dec. 31, 2022 | 0 | 167.9 | 23.8 | ||||||
Beginning balance at Dec. 31, 2022 | 13,388.4 | $ 0 | $ 0.1 | 73.3 | (164.9) | 16,466.5 | $ (2,977.1) | 13,397.9 | (9.5) |
Net income | 387.6 | 387.9 | 387.9 | (0.3) | |||||
Other comprehensive income (loss), net of tax | (7.1) | (7.1) | (7.1) | ||||||
Capital contribution from noncontrolling interest | 0.2 | 0.2 | |||||||
Issuance of common stock under stock option and stock purchase plans, shares | 0.1 | ||||||||
Issuance of common stock under stock option and stock purchase plans | 20.1 | 20.1 | 20.1 | ||||||
Issuance of common stock under award plan, shares | 0.6 | ||||||||
Issuance of common stock under stock award plan | (80.2) | (80.2) | (80.2) | ||||||
Compensation related to share-based payments | 78.9 | 78.9 | 78.9 | ||||||
Other | (0.9) | (0.9) | (0.9) | ||||||
Ending balance at Mar. 31, 2023 | $ 13,787 | $ 0 | $ 0.1 | $ 91.2 | $ (172) | $ 16,854.4 | $ (2,977.1) | $ 13,796.6 | $ (9.6) |
Ending balance, shares at Mar. 31, 2023 | 0 | 168.6 | 23.8 |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2023 | |
Accounting Policies [Abstract] | |
Summary of significant accounting policies | References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries. Business Overview Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases worldwide. We have a broad portfolio of medicines to treat MS, have introduced the first approved treatment for SMA and co-developed two treatments to address a defining pathology of Alzheimer's disease. We are focused on advancing our pipeline in neurology, neuropsychiatry, specialized immunology and rare diseases. We support our drug discovery and development efforts through internal research and development programs and external collaborations. Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We also collaborate with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease, which was granted accelerated approval by the FDA in January 2023. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO, which was granted accelerated approval in the U.S. during the fourth quarter of 2022 for the treatment of relapsed or refractory follicular lymphoma; glofitamab, an investigational bispecific antibody for the potential treatment of non-Hodgkin's lymphoma; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group. In addition to continuing to invest in new potential innovation in MS and SMA we are advancing our mid-to-late stage programs including zuranolone for MDD and PPD, BIIB080 for Alzheimer's disease, QALSODY (tofersen) for ALS and both litifilimab and dapirolizumab pegol for certain forms of lupus. We also commercialize biosimilars of advanced biologics including BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe, as well as BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, in the U.S. We continue to develop potential biosimilar products including BIIB800, a proposed tocilizumab biosimilar referencing ACTEMRA, and SB15, a proposed aflibercept biosimilar referencing EYLEA. For additional information on our collaboration arrangements, please read Note 16, Collaborative and Other Relationships, to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). For additional information on our collaboration arrangements with Genentech, please read Note 19, Collaborative and Other Relationships, to our audited consolidated financial statements included in our 2022 Form 10-K. Basis of Presentation In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with U.S. GAAP. The information included in this quarterly report on Form 10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2022 Form 10-K. Our accounting policies are described in the Notes to Consolidated Financial Statements in our 2022 Form 10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S. GAAP. The results of operations for the three months ended March 31, 2023, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Consolidation Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners. Use of Estimates The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates. The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expense, reserves and allowances, the supply chain, manufacturing, clinical trials, research and development costs and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. Additionally, the ongoing geopolitical tensions related to the conflict in Ukraine, and the related sanctions and other penalties imposed, are creating substantial uncertainty in the global economy. The extent and duration of the conflict, sanctions and resulting market disruptions are highly unpredictable. We have made estimates of the impact of the COVID-19 pandemic and the ongoing geopolitical conflict within our condensed consolidated financial statements and there may be changes to those estimates in future periods. New Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have had or may have a material impact on our condensed consolidated financial statements or disclosures. Fair Value Measurements In June 2022 the FASB issued ASU No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions |
Dispositions
Dispositions | 3 Months Ended |
Mar. 31, 2023 | |
Divestitures [Abstract] | |
Dispositions | Sale of Joint Venture Equity Interest in Samsung Bioepis In April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics. Under the terms of this transaction, we received approximately $1.0 billion in cash at closing and expect to receive approximately $1.3 billion in cash to be deferred over two payments. The first payment of approximately $812.5 million was received in April 2023 and the second payment of approximately $437.5 million is due at the second anniversary of the closing of this transaction. Prior to the sale, the carrying value of our investment in Samsung Bioepis totaled $581.6 million. During the second quarter of 2022 we recognized a pre-tax gain of approximately $1.5 billion related to this transaction, which was recorded in other (income) expense, net in our condensed consolidated statements of income. This pre-tax gain included reclassifications from AOCI to net income of approximately $58.9 million in cumulative translation losses, partially offset by approximately $57.0 million in gains resulting from the termination of our net investment hedge. We elected the fair value option and measured the payments due to us from Samsung BioLogics at fair value. As of March 31, 2023, the estimated fair values of the first and second payments using risk-adjusted discount rates of 5.9% and 5.8% , respectively, were approximately $809.9 million and $411.6 million , respectively. These payments have been classified as Level 3 measurements and are reflected in other current assets and investments and other assets, respectively, in our condensed consolidated balance sheets. For the three months ended March 31, 2023, we recognized a gain of approximately $11.1 million and $6.2 million to reflect the changes in fair value related to the first and second payments due to us, respectively. These changes were recorded in other (income) expense, net in our condensed consolidated statements of income. As part of this transaction, we are also eligible to receive up to an additional $50.0 million upon the achievement of certain commercial milestones. Our policy for contingent payments of this nature is to recognize the payments in the period that they become realizable, which is generally the same period in which the payments are earned. |
Restructuring, Business Transfo
Restructuring, Business Transformation and Other Cost Saving Initiatives | 3 Months Ended |
Mar. 31, 2023 | |
Restructuring and Related Activities [Abstract] | |
Restructuring, Business Transformation and Other Cost Saving Initiatives | 2022 Cost Saving Initiatives In December 2021 and May 2022 we announced our plans to implement a series of cost-reduction measures during 2022. These savings are being achieved through a number of initiatives, including reductions to our workforce, the substantial elimination of our commercial ADUHELM infrastructure, the consolidation of certain real estate locations and operating efficiencies across our selling, general and administrative and research and development functions. Under these initiatives, we estimate we will incur total restructuring charges of approximately $135.0 million, primarily related to severance. These amounts were substantially incurred during 2022. As of March 31, 2023, $28.0 million remained in our restructuring reserve and payments are expected to be made through 2026. For the three months ended March 31, 2023 and 2022, we recognized $9.6 million and $38.1 million, respectively, of net pre-tax restructuring charges, of which approximately $7.1 million and $27.7 million, respectively, consisted of employee severance costs. These costs were recorded in restructuring charges in our condensed consolidated statements of income. Our restructuring reserve is included in accrued expense and other in our condensed consolidated balance sheets. In September 2022 we entered into an agreement to partially terminate a portion of our lease located at 300 Binney Street, as well as to reduce the lease term for the majority of the remaining space. This resulted in a gain of approximately $5.3 million, which was recorded within restructuring charges in our condensed consolidated statements of income during the third quarter of 2022. For additional information on our 300 Binney Street lease modification, please read Note 12, Leases , to our consolidated financial statements included in our 2022 Form 10-K. Following an evaluation of our current capacity needs, in March 2022 we ceased using a patient services office space in Durham, North Carolina. Our decision to cease use of the facility resulted in the immediate expense of certain leasehold improvements and other assets at this facility. As a result, we recognized approximately $10.4 million of accelerated depreciation expense, which was recorded in restructuring charges in our condensed consolidated statements of income for the three months ended March 31, 2022. In May 2022 we entered into a lease assignment agreement whereby we assigned our remaining lease obligations to an external third party. As a result of the lease assignment, we derecognized the related operating lease obligation and right-of-use asset during the second quarter of 2022. For the three months ended March 31, 2023, we recognized other restructuring costs of approximately $2.5 million, which were recorded in restructuring charges in our condensed consolidated statements of income. Other restructuring costs include items such as facility closure costs, employee non-severance expense, asset write-offs and other costs. Charges and spending related to our workforce reductions is summarized as follows: For the Three Months Ended March 31, (In millions) 2023 2022 Restructuring reserve as of December 31 $ 35.9 $ — Expense 7.1 27.7 Payment (15.6) (6.2) Foreign currency and other adjustments 0.6 — Restructuring reserve as of March 31 $ 28.0 — $ 21.5 |
Revenues
Revenues | 3 Months Ended |
Mar. 31, 2023 | |
Revenue from Contract with Customer [Abstract] | |
Revenues | Product Revenue Revenue by product is summarized as follows: For the Three Months Ended March 31, 2023 2022 (In millions) United Rest of Total United Rest of Total Multiple Sclerosis (MS): TECFIDERA $ 74.7 $ 199.8 $ 274.5 $ 117.1 $ 292.8 $ 409.9 VUMERITY 93.5 14.7 108.2 125.2 2.8 128.0 Total Fumarate 168.2 214.5 382.7 242.3 295.6 537.9 AVONEX 102.6 69.8 172.4 148.0 81.6 229.6 PLEGRIDY 29.9 43.3 73.2 34.3 45.7 80.0 Total Interferon 132.5 113.1 245.6 182.3 127.3 309.6 TYSABRI 245.4 227.4 472.8 284.5 236.3 520.8 FAMPYRA — 24.1 24.1 — 26.2 26.2 Subtotal: MS 546.1 579.1 1,125.2 709.1 685.4 1,394.5 Spinal Muscular Atrophy: SPINRAZA 146.7 296.6 443.3 163.3 309.2 472.5 Biosimilars: BENEPALI — 109.0 109.0 — 114.7 114.7 IMRALDI — 54.4 54.4 — 57.1 57.1 FLIXABI — 20.4 20.4 — 22.5 22.5 BYOOVIZ 8.2 0.4 8.6 — — — Subtotal: Biosimilars 8.2 184.2 192.4 — 194.3 194.3 Other (1) 0.4 2.0 2.4 2.8 2.2 5.0 Total product revenue $ 701.4 $ 1,061.9 $ 1,763.3 $ 875.2 $ 1,191.1 $ 2,066.3 (1) Other includes FUMADERM and ADUHELM. We recognized revenue from two wholesalers accounting for 27.3% and 7.4% of gross product revenue for the three months ended March 31, 2023, and 26.3% and 10.5% of gross product revenue for the three months ended March 31, 2022. An analysis of the change in reserves for discounts and allowances is summarized as follows: (In millions) Discounts Contractual Returns Total Balance, December 31, 2022 $ 153.8 $ 857.7 $ 23.5 $ 1,035.0 Current provisions relating to sales in current year 182.3 638.0 3.5 823.8 Adjustments relating to prior years (1.1) (8.1) 1.0 (8.2) Payments/credits relating to sales in current year (94.0) (261.8) (1.0) (356.8) Payments/credits relating to sales in prior years (73.3) (368.1) (7.4) (448.8) Balance, March 31, 2023 $ 167.7 $ 857.7 $ 19.6 $ 1,045.0 The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows: (In millions) As of March 31, 2023 As of December 31, 2022 Reduction of accounts receivable $ 137.8 $ 143.4 Component of accrued expense and other 907.2 891.6 Total revenue-related reserves $ 1,045.0 $ 1,035.0 Revenue from LEQEMBI Collaboration In January 2023 the FDA granted accelerated approval of LEQEMBI, which became commercially available in the U.S. during the first quarter of 2023. Upon commercialization, we began recognizing commercial profits and losses related to the LEQEMBI Collaboration Agreement on a net basis as a separate component of total revenue within our condensed consolidated income statements, as we are not the principal. For the three months ended March 31, 2023, we recognized a reduction to revenue of approximately $18.9 million, reflecting our net profit-share of the LEQEMBI Collaboration results in the U.S. For additional information on our collaboration arrangements with Eisai, please read Note 16, Collaborative and Other Relationships, to these condensed consolidated financial statements. Revenue from Anti-CD20 Therapeutic Programs Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN. For the Three Months Ended March 31, (In millions) 2023 2022 Royalty revenue on sales of OCREVUS $ 283.6 $ 252.3 Biogen’s share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO 112.5 143.2 Other revenue from anti-CD20 therapeutic programs 3.4 3.9 Total revenue from anti-CD20 therapeutic programs $ 399.5 $ 399.4 For additional information on our collaboration arrangements with Genentech, please read Note 19, Collaborative and Other Relationships, to our consolidated financial statements included in our 2022 Form 10-K. Contract Manufacturing, Royalty and Other Revenue Contract manufacturing, royalty and other revenue is summarized in the table below. For the Three Months Ended March 31, (In millions) 2023 2022 Contract manufacturing revenue $ 306.9 $ 47.5 Royalty and other revenue 12.2 18.6 Total contract manufacturing, royalty and other revenue $ 319.1 $ 66.1 Contract Manufacturing Revenue Contract manufacturing revenue primarily reflects amounts earned under contract manufacturing agreements with our strategic customers. During the first quarter of 2023 we began recognizing contract manufacturing revenue for LEQEMBI, upon accelerated approval of LEQEMBI in the U.S. Prior to accelerated approval, contract manufacturing amounts related to LEQEMBI were recognized in research and development within our condensed consolidated income statements. Royalty and Other Revenue Royalty and other revenue primarily reflects the royalties we receive from net sales on products related to patents that we have out-licensed, as well as royalty revenue on biosimilar products from our license arrangements with Samsung Bioepis. For additional information on our license arrangements with Samsung Bioepis, please read Note 16, Collaborative and Other Relationships , to these condensed consolidated financial statements. |
Inventory
Inventory | 3 Months Ended |
Mar. 31, 2023 | |
Inventory Disclosure [Abstract] | |
Inventory | The components of inventory are summarized as follows: (In millions) As of March 31, 2023 As of December 31, 2022 Raw materials $ 432.4 $ 413.2 Work in process 684.9 751.9 Finished goods 205.9 200.4 Total inventory $ 1,323.2 $ 1,365.5 Balance Sheet Classification: Inventory $ 1,281.0 $ 1,344.4 Investments and other assets 42.2 21.1 Total inventory $ 1,323.2 $ 1,365.5 During the first quarter of 2022 we wrote-off approximately $275.0 million of inventory related to ADUHELM, as a result of the final NCD, which was recognized in cost of sales within our condensed consolidated statements of income for the three months ended March 31, 2022. We recognized approximately $136.0 million related to Eisai's 45.0% share of these charges in collaboration profit sharing/(loss reimbursement) within our condensed consolidated statements of income for the three months ended March 31, 2022. As of March 31, 2023 and December 31, 2022, the carrying value of our ADUHELM inventory was immaterial. |
Intangible Assets and Goodwill
Intangible Assets and Goodwill | 3 Months Ended |
Mar. 31, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Intangible Assets and Goodwill | Intangible Assets Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows: As of March 31, 2023 As of December 31, 2022 (In millions) Estimated Life Cost Accumulated Net Cost Accumulated Net Completed technology 4-28 years $ 7,428.7 $ (5,679.4) $ 1,749.3 $ 7,415.3 $ (5,629.2) $ 1,786.1 Trademarks and trade names Indefinite 64.0 — 64.0 64.0 — 64.0 Total intangible assets $ 7,492.7 $ (5,679.4) $ 1,813.3 $ 7,479.3 $ (5,629.2) $ 1,850.1 Amortization and Impairments For the three months ended March 31, 2023, amortization and impairment of acquired intangible assets totaled $50.2 million, compared to $66.9 million in the prior year comparative period. The decrease was primarily due to a lower rate of amortization for acquired intangible assets. For the three months ended March 31, 2023 and 2022, we had no impairment charges. Completed Technology Completed technology primarily relates to our other marketed products and programs acquired through asset acquisitions, licenses and business combinations. Estimated Future Amortization of Intangible Assets The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows: (In millions) As of March 31, 2023 2023 (remaining nine months) $ 165.0 2024 195.0 2025 190.0 2026 175.0 2027 170.0 2028 165.0 Goodwill The following table provides a roll forward of the changes in our goodwill balance: (In millions) As of March 31, 2023 Goodwill, December 31, 2022 $ 5,749.0 Other 2.8 Goodwill, March 31, 2023 $ 5,751.8 As of March 31, 2023, we had no ac |
Fair Value Measurements
Fair Value Measurements | 3 Months Ended |
Mar. 31, 2023 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value: Fair Value Measurements on a Recurring Basis As of March 31, 2023 (In millions) Total Quoted Prices Significant Other Significant Assets: Cash equivalents $ 2,406.6 $ — $ 2,406.6 $ — Marketable debt securities: Corporate debt securities 1,704.2 — 1,704.2 — Government securities 1,285.0 — 1,285.0 — Mortgage and other asset backed securities 132.1 — 132.1 — Marketable equity securities 678.1 678.1 — — Other current assets: Receivable from Samsung BioLogics (1) 809.9 — — 809.9 Derivative contracts 35.1 — 35.1 — Other assets: Plan assets for deferred compensation 34.1 — 34.1 — Receivable from Samsung BioLogics (1) 411.6 — — 411.6 Total $ 7,496.7 $ 678.1 $ 5,597.1 $ 1,221.5 Liabilities: Derivative contracts $ 39.8 $ — $ 39.8 $ — Total $ 39.8 $ — $ 39.8 $ — (1) Represents the fair value of the current and non-current payments due from Samsung BioLogics as a result of the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. For additional information on the sale of our equity interest in Samsung Bioepis, please read Note 2, Dispositions, to these condensed consolidated financial statements. Fair Value Measurements on a Recurring Basis As of December 31, 2022 (In millions) Total Quoted Prices Significant Other Significant Assets: Cash equivalents $ 2,847.6 $ — $ 2,847.6 $ — Marketable debt securities: Corporate debt securities 1,231.6 — 1,231.6 — Government securities 810.3 — 810.3 — Mortgage and other asset backed securities 137.3 — 137.3 — Marketable equity securities 791.1 791.1 — — Other current assets: Receivable from Samsung BioLogics (1) 798.8 — — 798.8 Other assets: Derivative contracts 63.0 — 63.0 — Plan assets for deferred compensation 32.8 — 32.8 — Receivable from Samsung BioLogics (1) 405.4 — — 405.4 Total $ 7,117.9 $ 791.1 $ 5,122.6 $ 1,204.2 Liabilities: Derivative contracts $ 26.0 $ — $ 26.0 $ — Total $ 26.0 $ — $ 26.0 $ — (1) Represents the fair value of the current and non-current payments due from Samsung BioLogics as a result of the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. For additional information on the sale of our equity interest in Samsung Bioepis, please read Note 2, Dispositions, to these condensed consolidated financial statements. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities was determined through third-party pricing services. During the third quarter of 2022 we elected to early adopt ASU 2022-03 on a prospective basis, which resulted in removing the impact of contractual sale restrictions from the fair value measurement of our remaining Sage common stock subject to certain holding period restrictions. As of December 31, 2022, our entire investment in the common stock of Sage was classified as a Level 1 measurement. Prior to the adoption of this standard, the fair value of Level 2 instruments classified as marketable equity securities represented a portion of our investment in the common stock of Sage and was valued using an option pricing valuation model. Our investments in the common stock of Sangamo and Denali had holding period restrictions that expired during 2022. As of December 31, 2022, the fair values of our investments in Sangamo and Denali common stock were classified as Level 1 measurements. Although the contractual holding period restrictions on our investments in Denali, Sage and Sangamo have expired, our ability to liquidate these investments may be limited by the size of our interest, the volume of market related activity, our concentrated level of ownership and potential restrictions resulting from our status as a collaborator. Therefore, we may realize significantly less than the current value of such investments. For additional information on our investments in Denali, Sangamo and Sage common stock, please read Note 19, Collaborative and Other Relationships , to our consolidated financial statements included in our 2022 Form 10-K. There have been no material impairments of our assets measured and carried at fair value as of March 31, 2023 and December 31, 2022. In addition, there have been no changes to our valuation techniques as of March 31, 2023 and December 31, 2022. For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read Note 1, Summary of Significant Accounting Policies - Fair Value Measurements, to our consolidated financial statements included in our 2022 Form 10-K. Level 3 Assets and Liabilities Held at Fair Value There were no transfers of assets or liabilities into or out of Level 3 as of March 31, 2023 and December 31, 2022. Contingent Consideration Obligations In connection with our acquisition of Convergence, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair value of our contingent consideration obligations, which were classified as Level 3 measurements: (In millions) For the three months ended March 31, 2022 Fair value, beginning of period $ 209.1 Changes in fair value (7.1) Fair value, end of period $ 202.0 Changes in the fair value of our contingent consideration obligations are recorded in (gain) loss on fair value remeasurement of contingent consideration in our condensed consolidated statements of income. During the fourth quarter of 2022 we discontinued further development efforts related to vixotrigine for the potential treatment of TGN and DPN, resulting in a reduction of our contingent consideration obligations of approximately $195.4 million, reducing the fair value of vixotrigine to zero. For the three months ended March 31, 2022, the changes in fair value of our contingent consideration obligations were primarily due to an increase in discount rates used to revalue these obligations and delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs. Financial Instruments Not Carried at Fair Value Other Financial Instruments Due to the short-term nature of certain financial instruments, the carrying value reflected in our condensed consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expense and other, approximates fair value. Debt Instruments The fair and carrying values of our debt instruments, which are Level 2 liabilities, are summarized as follows: As of March 31, 2023 As of December 31, 2022 (In millions) Fair Carrying Fair Carrying 4.050% Senior Notes due September 15, 2025 $ 1,711.6 $ 1,745.2 $ 1,699.9 $ 1,744.7 2.250% Senior Notes due May 1, 2030 1,262.2 1,493.1 1,219.0 1,492.9 5.200% Senior Notes due September 15, 2045 1,130.2 1,100.4 1,033.2 1,100.3 3.150% Senior Notes due May 1, 2050 1,043.7 1,473.9 989.0 1,473.8 3.250% Senior Notes due February 15, 2051 493.2 470.1 469.1 469.3 Total $ 5,640.9 $ 6,282.7 $ 5,410.2 $ 6,281.0 The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. The changes in the fair values of our Senior Notes as of March 31, 2023, compared to December 31, 2022, are primarily related to decreases in U.S. treasury yields used to value our Senior Notes since December 31, 2022. For additional information related to our Senior Notes, please read Note 13, Indebtedness, to our consolidated financial statements included in our 2022 Form 10-K. |
Financial Instruments
Financial Instruments | 3 Months Ended |
Mar. 31, 2023 | |
Investments, Debt and Equity Securities [Abstract] | |
Financial Instruments | The following table summarizes our financial assets with maturities of less than 90 days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets: (In millions) As of March 31, 2023 As of December 31, 2022 Commercial paper $ 64.0 $ 177.2 Overnight reverse repurchase agreements 300.3 59.0 Money market funds 2,042.3 2,581.5 Short-term debt securities — 29.9 Total $ 2,406.6 $ 2,847.6 The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. Our marketable equity securities gains (losses) are recorded in other (income) expense, net in our condensed consolidated statements of income. The following tables summarize our marketable debt and equity securities, classified as available-for-sale: As of March 31, 2023 (In millions) Amortized Gross Gross Fair Marketable debt securities Corporate debt securities: Current $ 1,287.6 $ 0.1 $ (4.4) $ 1,283.3 Non-current 423.4 1.0 (3.5) 420.9 Government securities: Current 863.5 0.1 (4.2) 859.4 Non-current 426.1 1.0 (1.5) 425.6 Mortgage and other asset backed securities: Current 0.4 — — 0.4 Non-current 132.9 0.1 (1.3) 131.7 Total marketable debt securities $ 3,133.9 $ 2.3 $ (14.9) $ 3,121.3 Marketable equity securities Marketable equity securities, current $ 87.7 $ — $ (19.8) $ 67.9 Marketable equity securities, non-current 1,001.1 — (390.9) 610.2 Total marketable equity securities $ 1,088.8 $ — $ (410.7) $ 678.1 As of December 31, 2022 (In millions) Amortized Gross Gross Fair Marketable debt securities Corporate debt securities: Current $ 936.2 $ — $ (4.9) $ 931.3 Non-current 305.3 0.1 (5.1) 300.3 Government securities: Current 547.1 0.1 (5.0) 542.2 Non-current 271.4 — (3.3) 268.1 Mortgage and other asset backed securities: Current — — — — Non-current 139.1 0.1 (1.9) 137.3 Total marketable debt securities $ 2,199.1 $ 0.3 $ (20.2) $ 2,179.2 Marketable equity securities Marketable equity securities, non-current $ 1,133.8 $ — $ (342.7) $ 791.1 Total marketable equity securities $ 1,133.8 $ — $ (342.7) $ 791.1 Summary of Contractual Maturities: Available-for-Sale Debt Securities The estimated fair value and amortized cost of our marketable debt securities classified as available-for-sale by contractual maturity are summarized as follows: As of March 31, 2023 As of December 31, 2022 (In millions) Estimated Amortized Estimated Amortized Due in one year or less $ 2,143.1 $ 2,151.5 $ 1,473.5 $ 1,483.3 Due after one year through five years 962.2 965.8 694.4 703.7 Due after five years 16.0 16.6 11.3 12.1 Total marketable debt securities $ 3,121.3 $ 3,133.9 $ 2,179.2 $ 2,199.1 The average maturity of our marketable debt securities classified as available-for-sale as of March 31, 2023 and December 31, 2022, was approximately 9 months and 8 months, respectively. Proceeds from Marketable Debt Securities The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows: For the Three Months Ended March 31, (In millions) 2023 2022 Proceeds from maturities and sales $ 406.7 $ 543.6 Realized gains 0.1 — Realized losses 0.7 0.6 Realized losses for the three months ended March 31, 2023, primarily relate to sales of U.S. treasuries and corporate bonds. Realized losses for the three months ended March 31, 2022, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities. Strategic Investments As of March 31, 2023 and December 31, 2022, our strategic investment portfolio was comprised of investments totaling $733.6 million and $846.0 million, respectively, which are included in investments and other assets in our condensed consolidated balance sheets. Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in Note 7, Fair Value Measurements, to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. The decrease in our strategic investment portfolio as of March 31, 2023, was primarily due to a decrease in the fair value of our investments in Denali, Sangamo and Ionis common stock. For additional information on our investments in Denali, Sangamo, Sage and Ionis common stock, please read Note 19, Collaborative and Other Relationships , to our consolidated financial statements included in our 2022 Form 10-K. |
Derivative Instruments
Derivative Instruments | 3 Months Ended |
Mar. 31, 2023 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Derivative Instruments | Foreign Currency Forward Contracts - Hedging Instruments Due to the global nature of our operations, portions of our revenue and operating expense are recorded in currencies other than the U.S. dollar. The value of revenue and operating expense measured in U.S. dollars is therefore subject to changes in foreign currency exchange rates. We enter into foreign currency forward contracts and foreign currency options with financial institutions with the primary objective to mitigate the impact of foreign currency exchange rate fluctuations on our international revenue and operating expense. Foreign currency forward contracts and foreign currency options in effect as of March 31, 2023 and December 31, 2022, had durations of 1 to 18 months and 1 to 12 months, respectively. These contracts have been designated as cash flow hedges and unrealized gains and losses on the portion of these foreign currency forward contracts and foreign currency options that are included in the effectiveness test are reported in AOCI. Realized gains and losses of such contracts and options are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expense when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from AOCI and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that have been impacted by the hedged item. The notional amount of foreign currency forward contracts and foreign currency options that were entered into to hedge forecasted revenue and operating expense is summarized as follows: Notional Amount (In millions) As of March 31, 2023 As of December 31, 2022 Euro $ 1,854.8 $ 1,495.5 British pound 124.3 162.8 Swiss franc 248.2 — Canadian dollar 43.3 57.2 Total foreign currency contracts and options $ 2,270.6 $ 1,715.5 The pre-tax portion of the fair value of these foreign currency forward contracts and foreign currency options that were included in AOCI in total equity is summarized as follows: (In millions) As of March 31, 2023 As of December 31, 2022 Unrealized gains $ 8.8 $ 29.9 Unrealized (losses) (39.0) (21.3) Net unrealized gains (losses) $ (30.2) $ 8.6 We expect the net unrealized losses of approximately $30.2 million to be settled over the next 18 months, of which approximately $30.0 million of these net unrealized losses are expected to be settled over the next 12 months, with any amounts in AOCI to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties’ credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of March 31, 2023 and December 31, 2022, credit risk did not materially change the fair value of our foreign currency forward contracts and forward currency options. The following table summarizes the effect of foreign currency forward contracts and forward currency options designated as hedging instruments in our condensed consolidated statements of income: For the Three Months Ended March 31, Net Gains/(Losses) Net Gains/(Losses) Location 2023 2022 Location 2023 2022 Revenue $ 17.6 $ 20.9 Revenue $ 1.6 $ (6.5) Operating expense (0.5) (0.3) Operating expense (2.1) (0.1) Net Investment Hedges - Hedging Instruments In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5.0% to approximately 49.9%. In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we entered into foreign currency forward contracts. These contracts were designated as net investment hedges. In April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics and closed these foreign currency forward contracts. Upon completing this sale, the cumulative gains on our net investment hedges of $57.0 million were reclassified from AOCI and reflected within the total pre-tax gain recognized from the sale, which was recorded in other (income) expense, net in our condensed consolidated statements of income. For additional information on the sale of our equity interest in Samsung Bioepis, please read Note 2, Dispositions, to these condensed consolidated financial statements. The following table summarizes the effect of our net investment hedges in our condensed consolidated financial statements: For the Three Months Ended March 31, Net Gains/(Losses) Net Gains/(Losses) Net Gains/(Losses) Location 2022 Location 2022 Location 2022 Gains (losses) on net investment hedges (1) $ 10.1 Gains (losses) on net investment hedges (1) $ (3.3) Other (income) expense (1) $ (1.1) (1) Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read Note 2, Dispositions, to these condensed consolidated financial statements. For additional information on our collaboration arrangements with Samsung Bioepis, please read Note 16, Collaborative and Other Relationships, to these condensed consolidated financial statements. Foreign Currency Forward Contracts - Other Derivative Instruments We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions. The aggregate notional amount of these outstanding foreign currency forward contracts was $1,436.3 million and $1,238.8 million as of March 31, 2023 and December 31, 2022, respectively. Net gains of $1.8 million and net losses of $12.2 million related to these contracts were recorded as a component of other (income) expense, net for the three months ended March 31, 2023 and 2022, respectively. Summary of Derivative Instruments While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset. The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments: (In millions) Balance Sheet Location As of March 31, 2023 As of December 31, 2022 Cash Flow Hedging Instruments: Asset derivative instruments Other current assets $ 12.3 $ 37.9 Investments and other assets 0.1 — Liability derivative instruments Accrued expense and other 31.9 18.4 Other long-term liabilities 0.3 — Other Derivative Instruments: Asset derivative instruments Other current assets 22.7 25.1 Liability derivative instruments Accrued expense and other 7.6 7.6 |
Property, Plant and Equipment
Property, Plant and Equipment | 3 Months Ended |
Mar. 31, 2023 | |
Property, Plant and Equipment [Abstract] | |
Property, Plant and Equipment | Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $2,218.2 million and $2,165.7 million as of March 31, 2023 and December 31, 2022, respectively. For the three months ended March 31, 2023, depreciation expense totaled $62.1 million compared to $76.3 million in the prior year comparative period. Solothurn, Switzerland Manufacturing Facility In order to support our future growth and drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. Upon completion, this facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of March 31, 2023 and December 31, 2022, we had approximately $721.2 million and $711.1 million, respectively, capitalized as construction in progress related to this facility. Solothurn has been approved for the manufacture of ADUHELM and LEQEMBI by the FDA. In the second quarter of 2021 a portion of the Solothurn manufacturing facility was placed into service and we estimate the second manufacturing suite will be operational by the end of 2023. |
Equity
Equity | 3 Months Ended |
Mar. 31, 2023 | |
Equity [Abstract] | |
Equity | Share Repurchases In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. There were no share repurchases of our common stock during the three months ended March 31, 2023 and 2022. Approximately $2.1 billion remained available under our 2020 Share Repurchase Program as of March 31, 2023. Accumulated Other Comprehensive Income (Loss) The following tables summarize the changes in AOCI, net of tax by component: March 31, 2023 (In millions) Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax Currency Translation Adjustments Total Balance, December 31, 2022 $ (15.7) $ 15.1 $ (1.1) $ (163.2) $ (164.9) Other comprehensive income (loss) before reclassifications 5.3 (20.3) 0.5 22.1 7.6 Amounts reclassified from AOCI 0.4 (15.1) — — (14.7) Net current period other comprehensive income (loss) 5.7 (35.4) 0.5 22.1 (7.1) Balance, March 31, 2023 $ (10.0) $ (20.3) $ (0.6) $ (141.1) $ (172.0) March 31, 2022 (In millions) Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax Gains (Losses) on Net Investment Hedges, Net of Tax (1) Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax Currency Translation Adjustments Total Balance, December 31, 2021 $ (2.2) $ 53.8 $ 25.5 $ (44.8) $ (139.0) $ (106.7) Other comprehensive income (loss) before reclassifications (10.2) 34.4 5.1 0.9 (21.8) 8.4 Amounts reclassified from AOCI 0.5 (18.5) 1.1 — — (16.9) Net current period other comprehensive income (loss) (9.7) 15.9 6.2 0.9 (21.8) (8.5) Balance, March 31, 2022 $ (11.9) $ 69.7 $ 31.7 $ (43.9) $ (160.8) $ (115.2) (1) Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read Note 2, Dispositions, to these condensed consolidated financial statements. The following table summarizes the amounts reclassified from AOCI: (In millions) Amounts Reclassified from AOCI Income Statement Location For the Three Months Ended March 31, 2023 2022 Gains (losses) on securities available for sale $ (0.5) $ (0.6) Other (income) expense 0.1 0.1 Income tax (benefit) expense Gains (losses) on cash flow hedges 17.6 20.9 Revenue (0.5) (0.3) Operating expense (0.1) (0.1) Other (income) expense (1.9) (2.0) Income tax (benefit) expense Gains (losses) on net investment hedges (1) — (1.1) Other (income) expense Total reclassifications, net of tax $ 14.7 $ 16.9 (1) Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read Note 2, Dispositions, to these condensed consolidated financial statements. |
Earnings per Share
Earnings per Share | 3 Months Ended |
Mar. 31, 2023 | |
Earnings Per Share [Abstract] | |
Earnings per Share | Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows: For the Three Months Ended March 31, (In millions) 2023 2022 Numerator: Net income attributable to Biogen Inc. $ 387.9 $ 303.8 Denominator: Weighted average number of common shares outstanding 144.4 147.1 Effect of dilutive securities: Time-vested restricted stock units 0.6 0.3 Market stock units 0.1 0.1 Performance stock units settled in stock 0.1 0.1 Dilutive potential common shares 0.8 0.5 Shares used in calculating diluted earnings per share 145.2 147.6 Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant. |
Share-based Payments
Share-based Payments | 3 Months Ended |
Mar. 31, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
Share-based Payments | Share-based Compensation Expense The following table summarizes share-based compensation expense included in our condensed consolidated statements of income: For the Three Months Ended March 31, (In millions) 2023 2022 Research and development $ 31.3 $ 25.7 Selling, general and administrative 50.1 46.1 Subtotal 81.4 71.8 Capitalized share-based compensation costs (3.3) (2.8) Share-based compensation expense included in total cost and expense 78.1 69.0 Income tax effect (14.7) (12.8) Share-based compensation expense included in net income attributable to Biogen Inc. $ 63.4 $ 56.2 The following table summarizes share-based compensation expense associated with each of our share-based compensation programs: For the Three Months Ended March 31, (In millions) 2023 2022 Market stock units $ 2.2 $ 5.9 Time-vested restricted stock units 61.7 51.3 Performance stock units settled in stock 9.5 8.3 Performance stock units settled in cash 2.5 1.4 Employee stock purchase plan 4.7 4.9 Stock options (1) 0.8 — Subtotal 81.4 71.8 Capitalized share-based compensation costs (3.3) (2.8) Share-based compensation expense included in total cost and expense $ 78.1 $ 69.0 (1) During the fourth quarter of 2022 we granted stock options. For additional information, please read Note 16, Share-Based Payments , to our consolidated financial statements included in our 2022 Form 10-K. We estimate the fair value of our obligations associated with our performance stock units settled in cash at the end of each reporting period through expected settlement. Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions. |
Income Taxes
Income Taxes | 3 Months Ended |
Mar. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Tax Rate A reconciliation between the U.S. federal statutory tax rate and our effective tax rate is summarized as follows: For the Three Months Ended March 31, 2023 2022 Statutory rate 21.0 % 21.0 % State taxes 1.3 (0.4) Taxes on foreign earnings (5.6) (10.8) Tax credits (6.6) (2.5) Purchased intangible assets 0.4 0.6 GILTI 0.5 0.3 Neurimmune tax impacts — 24.2 Other 0.6 3.8 Effective tax rate 11.6 % 36.2 % Changes in Tax Rate For the three months ended March 31, 2023, compared to the same period in 2022, the decrease in our effective tax rate, excluding the impact of the net Neurimmune deferred tax asset, as discussed below, includes the resolution of an uncertain tax matter in the current quarter related to tax credits and the non-cash tax effects of changes in the value of our equity investments. The tax effects of this change in value of our equity investments are recorded discretely since changes in value of equity investments cannot be forecasted. Neurimmune Deferred Tax Asset During the first quarter of 2022, upon issuance of the final NCD related to ADUHELM, we recorded an increase in a valuation allowance of approximately $85.0 million to reduce the net value of a previously recorded deferred tax asset to zero. This adjustment to our net deferred tax asset is recorded with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc. For additional information on our collaboration arrangement with Neurimmune, please read Note 17, Investments in Variable Interest Entities , to these condensed consolidated financial statements. Accounting for Uncertainty in Income Taxes We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2017 or state, local or non-U.S. income tax examinations for years before 2013. The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations. It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities. We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could decrease by up to approximately $500.0 million, including approximately $450.0 million related to the unrecognized |
Other Consolidated Financial St
Other Consolidated Financial Statement Detail | 3 Months Ended |
Mar. 31, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Other Consolidated Financial Statement Detail | Other (Income) Expense, Net Components of other (income) expense, net, are summarized as follows: For the Three Months Ended March 31, (In millions) 2023 2022 Interest income $ (80.9) $ (2.9) Interest expense 62.5 66.1 (Gains) losses on investments, net 77.7 191.1 Foreign exchange (gains) losses, net 10.7 8.3 Other, net (0.6) 0.7 Total other (income) expense, net $ 69.4 $ 263.3 The (gains) losses on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. The following table summarizes our (gains) losses on investments, net that relate to our equity securities held during the following periods: For the Three Months Ended March 31, (In millions) 2023 2022 Net (gains) losses recognized on equity securities $ 78.1 $ 190.7 Less: Net (gains) losses realized on equity securities 1.6 (0.2) Net unrealized (gains) losses recognized on equity securities $ 76.5 $ 190.9 The net unrealized losses recognized during the three months ended March 31, 2023, primarily reflect a decrease in the aggregate fair value of our investments in Denali, Sangamo and Ionis common stock of approximately $100.0 million, partially offset by an increase in the fair value of Sage common stock of approximately $23.8 million. The net unrealized losses recognized during the three months ended March 31, 2022, primarily reflect a decrease in the aggregate fair value of our investments in Denali, Sage and Sangamo common stock of approximately $205.5 million, partially offset by an increase in the fair value of Ionis common stock of approximately $19.0 million. Accrued Expense and Other Accrued expense and other consists of the following: (In millions) As of March 31, 2023 As of December 31, 2022 Revenue-related reserves for discounts and allowances $ 907.2 $ 891.6 Employee compensation and benefits 187.2 395.6 Collaboration expense 265.5 277.9 Royalties and licensing fees 183.9 209.4 Other 744.4 746.9 Total accrued expense and other $ 2,288.2 $ 2,521.4 Other Long-term Liabilities Other long-term liabilities were $935.5 million and $944.2 million as of March 31, 2023 and December 31, 2022, respectively, and included accrued income taxes totaling $552.5 million and $541.7 million, respectively. |
Collaborative and Other Relatio
Collaborative and Other Relationships | 3 Months Ended |
Mar. 31, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Collaborative and Other Relationships | Note 16: Collaborative and Other Relationships Genentech, Inc. (Roche Group) We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO (mosunetuzumab), which was granted accelerated approval in the U.S. during the fourth quarter of 2022 for the treatment of relapsed or refractory follicular lymphoma; glofitamab, an investigational bispecific antibody for the potential treatment of non-Hodgkin's lymphoma; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN. RITUXAN Genentech and its affiliates are responsible for the worldwide manufacture of RITUXAN as well as all development and commercialization activities as follows: • U.S.: We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in the U.S. • Canada: We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in Canada. GAZYVA The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacture and commercialization of GAZYVA in the U.S. The level of gross sales of GAZYVA in the U.S. has impacted our percentage of the co-promotion profits for RITUXAN and LUNSUMIO, as summarized in the table below. OCREVUS Pursuant to the terms of our collaboration arrangements with Genentech, we receive a tiered royalty on U.S. net sales from 13.5% and increasing up to 24.0% if annual net sales exceed $900.0 million. There will be a 50.0% reduction to these royalties if a biosimilar to OCREVUS is approved in the U.S. In addition, we receive a gross 3.0% royalty on net sales of OCREVUS outside the U.S., with the royalty period lasting 11 years from the first commercial sale of OCREVUS on a country-by-country basis. The commercialization of OCREVUS does not impact the percentage of the co-promotion profits we receive for RITUXAN, LUNSUMIO or GAZYVA. Genentech is solely responsible for development and commercialization of OCREVUS and funding future costs. Genentech cannot develop OCREVUS in CLL, non-Hodgkin's lymphoma or rheumatoid arthritis. OCREVUS royalty revenue is based on our estimates from third-party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenue will be adjusted for in the period in which they become known, which is generally expected to be the following quarter. LUNSUMIO (mosunetuzumab) In January 2022 we exercised our option with Genentech to participate in the joint development and commercialization of LUNSUMIO. Under our collaboration with Genentech, we were responsible for 30.0% of development costs for LUNSUMIO prior to FDA approval and will be entitled to a tiered share of co-promotion operating profits and losses in the U.S., as summarized in the table below. In addition, we receive low single-digit royalties on sales of LUNSUMIO outside the U.S. In December 2022 LUNSUMIO was granted accelerated approval by the FDA for the treatment of relapsed or refractory follicular lymphoma. Prior to regulatory approval, we record our share of the expense incurred by the collaboration for the development of anti-CD20 products in research and development expense and pre-commercialization costs within selling, general and administrative expense in our condensed consolidated statements of income. After an anti-CD20 product is approved, we record our share of the development and sales and marketing expense related to that product as a reduction of our share of pre-tax profits in revenue from anti-CD20 therapeutic programs. Profit-sharing Formulas RITUXAN and LUNSUMIO Profit Share Our current pretax co-promotion profit-sharing formula for RITUXAN and LUNSUMIO in the U.S. provides for a 30.0% share on the first $50.0 million of combined co-promotion operating profits earned each calendar year. As a result of the FDA approval of LUNSUMIO our share of the combined annual co-promotion profits for RITUXAN and LUNSUMIO in excess of $50.0 million varies upon the following events, as summarized in the table below: After LUNSUMIO Approval until the First Threshold Date 37.5 % After First Threshold Date until the Second Threshold Date 35.0 % After Second Threshold Date 30.0 % First Threshold Date means the earlier of (i) the first day of the calendar quarter following the date U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $500.0 million or (ii) the first date in any calendar year in which U.S. gross sales of LUNSUMIO have reached $150.0 million. Second Threshold Date means the later of (i) the first date the gross sales in any calendar year in which U.S. gross sales of LUNSUMIO reach $350.0 million and (ii) January 1 of the calendar year following the calendar year in which the First Threshold Date occurs. In March 2023 the First Threshold Date was achieved. As a result, beginning in April 2023 the pre-tax profit share for RITUXAN and LUNSUMIO will be 35.0%. GAZYVA Profit Share Our current pretax profit-sharing formula for GAZYVA provides for a 35.0% share on the first $50.0 million of operating profits earned each calendar year. Our share of annual co-promotion profits in excess of $50.0 million varies upon the following events, as summarized in the table below: Until Second GAZYVA Threshold Date 37.5 % After Second GAZYVA Threshold Date 35.0 % Second GAZYVA Threshold Date means the first day of the calendar quarter following the date U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $500.0 million. The second GAZYVA threshold date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication. In March 2023 the Second GAZYVA Threshold Date was achieved. As a result, beginning in April 2023 the pre-tax profit share for GAZYVA will be 35.0%. Eisai Co., Ltd. As of March 31, 2023, we accrued a $31.0 million payable to Eisai related to the termination of an agreement whereby Eisai co-promoted or distributed our MS products in certain Asia-Pacific markets and settings. The termination fee is included in selling, general and administrative expense in our condensed consolidated statements of income for the three months ended March 31, 2023. LEQEMBI (lecanemab) Collaboration We have a collaboration agreement with Eisai to jointly develop and commercialize LEQEMBI (lecanemab), an anti-amyloid antibody for the potential treatment of Alzheimer's disease (the LEQEMBI Collaboration). Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both companies co-commercializing and co-promoting the product, and Eisai having final decision-making authority. All costs, including research, development, sales and marketing expense, are shared equally between us and Eisai. Upon LEQEMBI marketing approval, we and Eisai will co-promote LEQEMBI and share profits and losses equally. We currently manufacture LEQEMBI drug substance and drug product and in March 2022 we extended our supply agreement with Eisai related to LEQEMBI from five years to ten years for the manufacture of LEQEMBI drug substance. In January 2023 the FDA granted accelerated approval of LEQEMBI, which became commercially available in the U.S. during the first quarter of 2023. Upon commercialization, we began recognizing commercial profits and losses related to the LEQEMBI Collaboration Agreement on a net basis. As we are not the principal on sales transactions related to LEQEMBI, our 50.0% share of the revenue and operating expense is recorded on a net basis in revenue from LEQEMBI Collaboration, which is a separate component of revenue within our condensed consolidated statements of income. For the three months ended March 31, 2023, we recognized a reduction to revenue of approximately $18.9 million, reflecting our net profit-share of the LEQEMBI Collaboration results in the U.S. This amount is included in revenue from LEQEMBI Collaboration within our condensed consolidated statements of income. During the first quarter of 2023, upon commercialization of LEQEMBI, we began recognizing our share of U.S. revenue, cost of sales and selling and marketing expense in revenue from LEQEMBI Collaboration within our condensed consolidated income statements. Our share of LEQEMBI development expense will continue to be recorded within research and development expense and, until commercial approval on a region by region basis, non-U.S. selling and marketing expense will continue to be recorded in selling, general and administrative expense within our condensed consolidated statements of income. A summary of development and sales and marketing expense related to the LEQEMBI Collaboration is as follows: For the Three Months Ended March 31, (In millions) 2023 2022 Total development expense incurred by the collaboration related to the advancement of LEQEMBI $ 107.9 $ 77.0 Biogen's share of the LEQEMBI Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income 54.0 38.5 Total sales and marketing expense incurred by the LEQEMBI Collaboration (1) 10.5 15.9 Biogen's share of the LEQEMBI Collaboration sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income (1) 5.3 8.0 (1) Beginning in the first quarter of 2023 reimbursement to Eisai for our share of U.S. LEQEMBI selling, general and administrative expense is recognized in revenue from LEQEMBI Collaboration within our condensed consolidated statements of income. ADUHELM Collaboration Agreement The LEQEMBI Collaboration also provided Eisai with an option to jointly develop and commercialize ADUHELM (aducanumab) (ADUHELM Option). In October 2017 Eisai Exercised its ADUHELM Option and we entered into a new collaboration agreement for the joint development and commercialization of ADUHELM (the ADUHELM Collaboration Agreement). Under our initial ADUHELM Collaboration Agreement, we would lead the ongoing development of ADUHELM, and we and Eisai would co-promote ADUHELM with a region-based profit split. Beginning in 2019, Eisai was reimbursing us for 45.0% of development and sales and marketing expense incurred by the collaboration for the advancement of ADUHELM. In March 2022 we amended our ADUHELM Collaboration Agreement with Eisai. As of the amendment date, we have sole decision making and commercialization rights worldwide on ADUHELM, and beginning January 1, 2023, Eisai receives only a tiered royalty based on net sales of ADUHELM, and no longer participates in sharing ADUHELM's global profits and losses. Eisai's share of development, commercialization and manufacturing expense was limited to $335.0 million for the period from January 1, 2022 to December 31, 2022, which was achieved as of December 31, 2022. Once this limit was achieved, we became responsible for all ADUHELM related costs. A summary of development expense and sales and marketing expense related to our initial ADUHELM Collaboration Agreement is as follows: For the Three Months Ended March 31, (In millions) 2022 Total ADUHELM Collaboration development expense $ 44.2 Biogen's share of ADUHELM Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income 24.3 Total sales and marketing expense incurred by the ADUHELM Collaboration Agreement 95.0 Biogen's share of ADUHELM Collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income 50.9 ADUHELM C o-promotion Profits and Losses Under our initial ADUHELM Collaboration Agreement, we recognized revenue on sales of ADUHELM in the U.S. to third parties as a component of product revenue in our condensed consolidated statements of income. We also recorded the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income as these costs were incurred. Payments made to and received from Eisai for its 45.0% share of the co-promotion profits or losses in the U.S. were recognized in collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income. For the three months ended March 31, 2022, we recognized a net reduction to our operating expense of approximately $181.7 million to reflect Eisai's 45.0% share of net collaboration losses in the U.S. During the first quarter of 2022, as a result of the final NCD, we recorded approximately $275.0 million of charges associated with the write-off of inventory and purchase commitments in excess of forecasted demand related to ADUHELM. Additionally, for the three months ended March 31, 2022, we recorded approximately $45.0 million of aggregate gross idle capacity charges related to ADUHELM. These charges were recorded in cost of sales within our condensed consolidated statements of income. We recognized approximately $160.0 million related to Eisai's 45.0% share of these charges in collaboration profit sharing/(loss reimbursement) within our condensed consolidated statements of income for the three months ended March 31, 2022. Amounts receivable from Eisai related to the agreements discussed above were approximately $72.6 million and $88.0 million as of March 31, 2023 and December 31, 2022 , respectively. Amounts payable to Eisai related to the agreements discussed above were $137.8 million and $81.2 million as of March 31, 2023 and December 31, 2022, respectively . For additional information on our collaboration arrangements with Eisai, please read Note 19, Collaborative and Other Relationships, to our consolidated financial statements included in our 2022 Form 10-K. UCB We have a collaboration agreement with UCB, effective November 2003, to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of SLE and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity. All costs incurred for agreed indications, including research, development, sales and marketing expense, are shared equally between us and UCB. If marketing approval is obtained, both companies will co-promote dapirolizumab pegol and share profits and losses equally. A summary of development expense related to the UCB collaboration agreement is as follows: For the Three Months Ended March 31, (In millions) 2023 2022 Total UCB collaboration development expense $ 18.3 $ 17.6 Biogen's share of UCB collaboration development expense reflected in research and development expense in our condensed consolidated statements of income 9.2 8.8 Sage Therapeutics, Inc. In November 2020 we entered into a global collaboration and license agreement with Sage to jointly develop and commercialize zuranolone for the potential treatment of MDD and PPD and BIIB124 (SAGE-324) for the potential treatment of essential tremor with potential in other neurological conditions such as epilepsy. Under this collaboration, both companies will share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside of the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and may pay Sage potential tiered royalties in the high teens to low twenties. We may pay Sage milestones totaling $225.0 million upon the first commercial sale of zuranolone, for the potential treatment of MDD and PPD, in the U.S. A summary of development and sales and marketing expense related to this collaboration is as follows: For the Three Months Ended March 31, (In millions) 2023 2022 Total Sage collaboration development expense $ 34.8 $ 38.7 Biogen's share of Sage collaboration development expense reflected in research and development expense in our condensed consolidated statements of income 17.4 19.4 Total Sage sales and marketing expense incurred by the collaboration 38.2 18.4 Biogen's share of Sage collaboration sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income 19.1 9.2 Denali Therapeutics Inc. In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of LRRK2 for Parkinson's disease. In addition to the LRRK2 program, we also have an exclusive option to license two preclinical programs from Denali’s Transport Vehicle platform, including its ATV enabled anti-amyloid beta program and a second program utilizing its Transport Vehicle technology. Further, we have the right of first negotiation on two additional ATV-enabled therapeutics for indications within specific neurodegenerative diseases, should Denali decide to seek a collaboration for such programs. In April 2023 we exercised our option with Denali to license the ATV-enabled anti-amyloid beta program. In connection with this exercise, we will assume responsibility for all development and commercial activities and associated expenses related to the program. In addition, we will make a one-time option exercise payment to Denali and, should certain milestones be achieved, may pay Denali additional development and commercial milestone payments and royalties based on future net sales. Under this collaboration, both companies share responsibility and costs for global development based on specified percentages as well as profits and losses for commercialization in the U.S. and China. Outside the U.S. and China we are responsible for commercialization and may pay Denali potential tiered royalties. A summary of development expense related to this collaboration is as follows: For the Three Months Ended March 31, (In millions) 2023 2022 Total Denali collaboration development expense $ 16.6 $ 14.9 Biogen's share of Denali collaboration development expense reflected in research and development expense in our condensed consolidated statements of income 10.0 8.9 Sangamo Therapeutics, Inc. In February 2020 we entered into a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including Alzheimer's disease; ST-502 for synucleinopathies, including Parkinson’s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period. The companies are leveraging Sangamo’s proprietary zinc finger protein technology delivered via adeno-associated virus to modulate the expression of key genes involved in neurological diseases. In March 2023 we terminated our collaboration and license agreement with Sangamo. A summary of development expense related to this collaboration is as follows: For the Three Months Ended March 31, (In millions) 2023 2022 Total Sangamo collaboration development expense $ 5.1 $ 8.3 Biogen's share of Sangamo collaboration development expense reflected in research and development expense in our condensed consolidated statements of income 2.3 5.5 Other Research and Discovery Arrangements These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years. Other In July 2021 we entered into a collaboration and license agreement with InnoCare Pharma Limited for orelabrutinib, an oral small molecule Bruton's tyrosine kinase inhibitor for the potential treatment of MS. This license and collaboration agreement was later terminated in February 2023. For the three months ended March 31, 2023, we recorded $0.2 million as research and development expense in our condensed consolidated statements of income related to other research and discovery related arrangements, compared to $19.5 million in the prior year comparative period. Samsung Bioepis Co., Ltd. 2019 Development and Commercialization Agreement In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, BYOOVIZ (ranibizumab-nuna), a ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us at a pre-specified gross margin of approximately 45.0%. In connection with this transaction, we may also pay Samsung Bioepis up to approximately $180.0 million in additional development, regulatory and sales-based milestones. We also acquired an option to extend the term of our 2013 c ommercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional five years, subject to payment of an option exercise fee of $60.0 million, and obtained an option to acquire exclusive rights to commercialize these products in China. 2013 Commercial Agreement We reflect revenue on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenue in our condensed consolidated statements of income and record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income to their respective line items when these costs are incurred. We share 50.0% of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income. For the three months ended March 31, 2023, we recognized net profit-sharing expense of $57.1 million to reflect Samsung Bioepis' 50.0% sharing of the net collaboration profits, compared to a net profit-sharing expense of $64.4 million in the prior year comparative period. Other Services Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement with Samsung Bioepis. Under the license agreement, we granted Samsung Bioepis an exclusive license to use, develop, manufacture and commercialize biosimilar products created by Samsung Bioepis using Biogen product-specific technology. In exchange, we receive single digit royalties on biosimilar products developed and commercialized by Samsung Bioepis. Royalty revenue under the license agreement is recognized as a component of contract manufacturing, royalty and other revenue in our condensed consolidated statements of income. Amounts receivable from Samsung Bioepis related to the agreements discussed abo ve were $6.3 million a nd $2.0 million as of March 31, 2023 and December 31, 2022, respectively. Amounts payable to Samsung Bioepis related to the agreements discussed abo ve were $32.2 million and $40.5 million as of March 31, 2023 and December 31, 2022, respectively. For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read Note 19, Collaborative and Other Relationships, |
Investments in Variable Interes
Investments in Variable Interest Entities | 3 Months Ended |
Mar. 31, 2023 | |
Investments in Variable Interest Entities [Abstract] | |
Investments in Variable Interest Entities | Consolidated Variable Interest Entities Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities. Neurimmune SubOne AG We have a collaboration and license agreement with Neurimmune for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including ADUHELM (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all collaboration products. The Neurimmune Agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of a licensed product. We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity’s economic performance and we are required to fund 100.0% of the research and development costs incurred in support of the collaboration. Our royalty rates payable on products developed under the Neurimmune Agreement, including royalty rates payable on commercial sales of ADUHELM, range from the high single digits to sub-teens. During the first quarter of 2022, upon issuance of the final NCD related to ADUHELM, we recorded an increase in a valuation allowance of approximately $85.0 million to reduce the net value of a previously recorded deferred tax asset to zero. This adjustment to our net deferred tax asset is recorded with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc. Excluding the impact of the Neurimmune deferred tax asset, the assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts. Unconsolidated Variable Interest Entities We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. As of March 31, 2023 and December 31, 2022, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $28.0 million and $27.8 million, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments. We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previous contractually required amounts. For additional information on our investments in Neurimmune and other variable interest entities, please read Note 20, Investments in Variable Interest Entities, to our consolidated financial statements included in our 2022 Form 10-K. |
Litigation
Litigation | 3 Months Ended |
Mar. 31, 2023 | |
Loss Contingency, Information about Litigation Matters [Abstract] | |
Litigation | We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1, Summary of Significant Accounting Policies, to our consolidated financial statements included in our 2022 Form 10-K. With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties’ legal theories; and (v) the parties' settlement positions. If an estimate of the possible loss or range of loss can be made at this time, it is included in the potential loss contingency description below. The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties. Loss Contingencies ADUHELM Securities Litigation In March 2023 the United States District Court for the District of Massachusetts (the District Court) dismissed the previously disclosed shareholder action related to ADUHELM that had been filed in February 2022 against us and certain current and former officers. The second previously disclosed shareholder action related to ADUHELM, filed in November 2022 and dismissed by the District Court in September 2021, remains on appeal to the U.S. Court of Appeals for the First Circuit. Both actions alleged violations of federal securities laws under 15 U.S.C §78j(b) and §78t(a) and 17 C.F.R. §240.10b-5. Derivative Action We and members of the Board of Directors are named as defendants in derivative actions filed by shareholders in February and July 2022, in the U.S. District Court for the District of Massachusetts. The actions allege violations of federal securities laws under 15 U.S.C. §78n(a) and 17 C.F.R. §240 14.a-9, and breaches of fiduciary duties and waste of corporate assets, and seek declaratory and injunctive relief, monetary relief payable to Biogen, and attorneys’ fees and costs payable to the plaintiffs. The District Court has stayed both cases. IMRALDI Patent Litigation In June 2022 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) filed a claim for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis that Biogen commercializes in Europe, infringes the French counterpart of European Patent 3 145 488 (the EP ‘488 Patent), which expires in May 2035. In August 2022 Fresenius Kabi filed a claim for damages and injunctive relief against Biogen GmbH in the Düsseldorf Regional Court, alleging infringement of the German counterpart of the EP '488 Patent. A hearing in the Düsseldorf Regional Court has been set for December 2023. No hearing has been set in the French action. In July 2019 Gedeon Richter Nyrt (Gedeon Richter) filed a claim for damages and injunctive relief against Biogen GmbH in the Düsseldorf Regional Court, alleging infringement of the German counterpart of European Patent No. 3 212 667 (the EP '667 Patent), which expires in October 2035. The case has been stayed pending review by the TBA of the EPO of the EPO's decision revoking the '667 Patent. The TBA has set a hearing for July 2023. In November 2020 Gedeon Richter filed a claim for damages and injunctive relief against Biogen GmbH in the Düsseldorf Regional Court, alleging infringement of a German utility model corresponding to the EP '667 Patent, which expires in October 2025. The proceeding has been stayed pending the outcome of proceedings that Biogen has filed in the German Patent and Trademark Office to cancel the utility model, and the utility model was cancelled in March 2023. Dispute with Former Convergence Shareholders In 2015 Biogen acquired Convergence, a U.K. company. In November and December 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, sent us correspondence asserting claims of $200.0 million for alleged breach of the contract under which we acquired Convergence. We dispute the claims. ERISA Class Action Litigation In September 2020 the U.S. District Court for the District of Massachusetts consolidated two cases filed against us in July and August 2020 by participants in the Biogen 401(k) Savings Plan, alleging breach of fiduciary duty under ERISA. Plaintiffs seek a declaration of the action as a class action and monetary and other relief. Humana Patient Assistance Litigation In March 2023 the District Court for the District of Massachusetts dismissed the previously disclosed action filed against us by Humana in September 2020. Humana had alleged damages related to our providing MS patients with free medications and making charitable contributions to non-profit organizations that assist MS patients and had alleged violations of the federal RICO Act and state laws. Distributor Matter In December 2022 we terminated our distribution agreement with the distributor of products for Biogen in various countries in the Middle East and northern Africa. The former distributor has asserted breach of contract. No suit has been filed. Genentech Litigation In February 2023 Genentech, Inc. filed suit against us in the U.S. District Court for the Northern District of California, alleging that it is owed royalties on sales of TYSABRI that occurred after the expiration of a patent licensed by Genentech to Biogen, together with interest and costs. No trial date has been set. Other Matters Government Investigation The Company has received subpoenas from the Securities and Exchange Commission seeking information relating to ADUHELM, including healthcare sites and ADUHELM’s approval. TYSABRI Biosimilar Patent Matter In September 2022, following Sandoz Inc.'s announcement that the FDA had accepted its biologics license application for a proposed biosimilar referring to TYSABRI, we filed an action in the U.S. District Court for the District of Delaware against Sandoz Inc., other Sandoz entities and Polpharma Biologics S.A. under the Biologics Price Competition and Innovation Act, 42 U.S.C. §262, seeking a declaratory judgment of patent infringement. No trial has been set. Annulment Proceedings in the General Court of the European Union relating to TECFIDERA Pharmaceutical Works Polpharma and Mylan Ireland each filed actions in the General Court of the European Union (the General Court) (Polpharma in October 2018 and Mylan Ireland in November 2020) to annul the EMA's decision not to validate their applications to market generic versions of TECFIDERA on the grounds that TECFIDERA benefits from regulatory data protection. On May 5, 2021, the European General Court annulled the EMA's non-validation decision with respect to Polpharma. On March 16, 2023, the European Court of Justice set aside the judgment of the General Court and dismissed Polpharma's action. Product Liability and Other Legal Proceedings We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2023 | |
Accounting Policies [Abstract] | |
Overview | Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases worldwide. We have a broad portfolio of medicines to treat MS, have introduced the first approved treatment for SMA and co-developed two treatments to address a defining pathology of Alzheimer's disease. We are focused on advancing our pipeline in neurology, neuropsychiatry, specialized immunology and rare diseases. We support our drug discovery and development efforts through internal research and development programs and external collaborations. Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We also collaborate with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease, which was granted accelerated approval by the FDA in January 2023. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO, which was granted accelerated approval in the U.S. during the fourth quarter of 2022 for the treatment of relapsed or refractory follicular lymphoma; glofitamab, an investigational bispecific antibody for the potential treatment of non-Hodgkin's lymphoma; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group. In addition to continuing to invest in new potential innovation in MS and SMA we are advancing our mid-to-late stage programs including zuranolone for MDD and PPD, BIIB080 for Alzheimer's disease, QALSODY (tofersen) for ALS and both litifilimab and dapirolizumab pegol for certain forms of lupus. We also commercialize biosimilars of advanced biologics including BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe, as well as BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, in the U.S. We continue to develop potential biosimilar products including BIIB800, a proposed tocilizumab biosimilar referencing ACTEMRA, and SB15, a proposed aflibercept biosimilar referencing EYLEA. For additional information on our collaboration arrangements, please read Note 16, Collaborative and Other Relationships, to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). For additional information on our collaboration arrangements with Genentech, please read Note 19, Collaborative and Other Relationships, to our audited consolidated financial statements included in our 2022 Form 10-K. |
Basis of presentation | In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with U.S. GAAP. The information included in this quarterly report on Form 10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2022 Form 10-K. Our accounting policies are described in the Notes to Consolidated Financial Statements in our 2022 Form 10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S. GAAP. The results of operations for the three months ended March 31, 2023, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. |
Consolidation | Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners. |
Use of estimates | The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates. The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expense, reserves and allowances, the supply chain, manufacturing, clinical trials, research and development costs and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. Additionally, the ongoing geopolitical tensions related to the conflict in Ukraine, and the related sanctions and other penalties imposed, are creating substantial uncertainty in the global economy. The extent and duration of the conflict, sanctions and resulting market disruptions are highly unpredictable. We have made estimates of the impact of the COVID-19 pandemic and the ongoing geopolitical conflict within our condensed consolidated financial statements and there may be changes to those estimates in future periods. |
New accounting pronouncements | From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have had or may have a material impact on our condensed consolidated financial statements or disclosures. Fair Value Measurements In June 2022 the FASB issued ASU No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions |
Restructuring, Business Trans_2
Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Restructuring and Related Activities [Abstract] | |
Schedule of Restructuring Reserve by Type of Cost | harges and spending related to our workforce reductions is summarized as follows: For the Three Months Ended March 31, (In millions) 2023 2022 Restructuring reserve as of December 31 $ 35.9 $ — Expense 7.1 27.7 Payment (15.6) (6.2) Foreign currency and other adjustments 0.6 — Restructuring reserve as of March 31 $ 28.0 — $ 21.5 |
Revenues (Tables)
Revenues (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Revenue from Contract with Customer [Abstract] | |
Revenues by product | Revenue by product is summarized as follows: For the Three Months Ended March 31, 2023 2022 (In millions) United Rest of Total United Rest of Total Multiple Sclerosis (MS): TECFIDERA $ 74.7 $ 199.8 $ 274.5 $ 117.1 $ 292.8 $ 409.9 VUMERITY 93.5 14.7 108.2 125.2 2.8 128.0 Total Fumarate 168.2 214.5 382.7 242.3 295.6 537.9 AVONEX 102.6 69.8 172.4 148.0 81.6 229.6 PLEGRIDY 29.9 43.3 73.2 34.3 45.7 80.0 Total Interferon 132.5 113.1 245.6 182.3 127.3 309.6 TYSABRI 245.4 227.4 472.8 284.5 236.3 520.8 FAMPYRA — 24.1 24.1 — 26.2 26.2 Subtotal: MS 546.1 579.1 1,125.2 709.1 685.4 1,394.5 Spinal Muscular Atrophy: SPINRAZA 146.7 296.6 443.3 163.3 309.2 472.5 Biosimilars: BENEPALI — 109.0 109.0 — 114.7 114.7 IMRALDI — 54.4 54.4 — 57.1 57.1 FLIXABI — 20.4 20.4 — 22.5 22.5 BYOOVIZ 8.2 0.4 8.6 — — — Subtotal: Biosimilars 8.2 184.2 192.4 — 194.3 194.3 Other (1) 0.4 2.0 2.4 2.8 2.2 5.0 Total product revenue $ 701.4 $ 1,061.9 $ 1,763.3 $ 875.2 $ 1,191.1 $ 2,066.3 (1) Other includes FUMADERM and ADUHELM. |
Analysis of change In reserves | An analysis of the change in reserves for discounts and allowances is summarized as follows: (In millions) Discounts Contractual Returns Total Balance, December 31, 2022 $ 153.8 $ 857.7 $ 23.5 $ 1,035.0 Current provisions relating to sales in current year 182.3 638.0 3.5 823.8 Adjustments relating to prior years (1.1) (8.1) 1.0 (8.2) Payments/credits relating to sales in current year (94.0) (261.8) (1.0) (356.8) Payments/credits relating to sales in prior years (73.3) (368.1) (7.4) (448.8) Balance, March 31, 2023 $ 167.7 $ 857.7 $ 19.6 $ 1,045.0 |
Total reserves included in consolidated balance sheets | The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows: (In millions) As of March 31, 2023 As of December 31, 2022 Reduction of accounts receivable $ 137.8 $ 143.4 Component of accrued expense and other 907.2 891.6 Total revenue-related reserves $ 1,045.0 $ 1,035.0 |
Revenues from anti-CD20 therapeutic programs | Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN. For the Three Months Ended March 31, (In millions) 2023 2022 Royalty revenue on sales of OCREVUS $ 283.6 $ 252.3 Biogen’s share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO 112.5 143.2 Other revenue from anti-CD20 therapeutic programs 3.4 3.9 Total revenue from anti-CD20 therapeutic programs $ 399.5 $ 399.4 |
Other revenues | For the Three Months Ended March 31, (In millions) 2023 2022 Contract manufacturing revenue $ 306.9 $ 47.5 Royalty and other revenue 12.2 18.6 Total contract manufacturing, royalty and other revenue $ 319.1 $ 66.1 |
Inventory (Tables)
Inventory (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Inventory Disclosure [Abstract] | |
Components of inventory | The components of inventory are summarized as follows: (In millions) As of March 31, 2023 As of December 31, 2022 Raw materials $ 432.4 $ 413.2 Work in process 684.9 751.9 Finished goods 205.9 200.4 Total inventory $ 1,323.2 $ 1,365.5 Balance Sheet Classification: Inventory $ 1,281.0 $ 1,344.4 Investments and other assets 42.2 21.1 Total inventory $ 1,323.2 $ 1,365.5 |
Intangible Assets and Goodwill
Intangible Assets and Goodwill (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Intangible assets | Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows: As of March 31, 2023 As of December 31, 2022 (In millions) Estimated Life Cost Accumulated Net Cost Accumulated Net Completed technology 4-28 years $ 7,428.7 $ (5,679.4) $ 1,749.3 $ 7,415.3 $ (5,629.2) $ 1,786.1 Trademarks and trade names Indefinite 64.0 — 64.0 64.0 — 64.0 Total intangible assets $ 7,492.7 $ (5,679.4) $ 1,813.3 $ 7,479.3 $ (5,629.2) $ 1,850.1 |
Estimated future amortization for acquired intangible assets | The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows: (In millions) As of March 31, 2023 2023 (remaining nine months) $ 165.0 2024 195.0 2025 190.0 2026 175.0 2027 170.0 2028 165.0 |
Summary of roll forward of the changes in goodwill | The following table provides a roll forward of the changes in our goodwill balance: (In millions) As of March 31, 2023 Goodwill, December 31, 2022 $ 5,749.0 Other 2.8 Goodwill, March 31, 2023 $ 5,751.8 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Fair Value Disclosures [Abstract] | |
Summary of assets and liabilities recorded at fair value | The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value: Fair Value Measurements on a Recurring Basis As of March 31, 2023 (In millions) Total Quoted Prices Significant Other Significant Assets: Cash equivalents $ 2,406.6 $ — $ 2,406.6 $ — Marketable debt securities: Corporate debt securities 1,704.2 — 1,704.2 — Government securities 1,285.0 — 1,285.0 — Mortgage and other asset backed securities 132.1 — 132.1 — Marketable equity securities 678.1 678.1 — — Other current assets: Receivable from Samsung BioLogics (1) 809.9 — — 809.9 Derivative contracts 35.1 — 35.1 — Other assets: Plan assets for deferred compensation 34.1 — 34.1 — Receivable from Samsung BioLogics (1) 411.6 — — 411.6 Total $ 7,496.7 $ 678.1 $ 5,597.1 $ 1,221.5 Liabilities: Derivative contracts $ 39.8 $ — $ 39.8 $ — Total $ 39.8 $ — $ 39.8 $ — (1) Represents the fair value of the current and non-current payments due from Samsung BioLogics as a result of the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. For additional information on the sale of our equity interest in Samsung Bioepis, please read Note 2, Dispositions, to these condensed consolidated financial statements. Fair Value Measurements on a Recurring Basis As of December 31, 2022 (In millions) Total Quoted Prices Significant Other Significant Assets: Cash equivalents $ 2,847.6 $ — $ 2,847.6 $ — Marketable debt securities: Corporate debt securities 1,231.6 — 1,231.6 — Government securities 810.3 — 810.3 — Mortgage and other asset backed securities 137.3 — 137.3 — Marketable equity securities 791.1 791.1 — — Other current assets: Receivable from Samsung BioLogics (1) 798.8 — — 798.8 Other assets: Derivative contracts 63.0 — 63.0 — Plan assets for deferred compensation 32.8 — 32.8 — Receivable from Samsung BioLogics (1) 405.4 — — 405.4 Total $ 7,117.9 $ 791.1 $ 5,122.6 $ 1,204.2 Liabilities: Derivative contracts $ 26.0 $ — $ 26.0 $ — Total $ 26.0 $ — $ 26.0 $ — (1) Represents the fair value of the current and non-current payments due from Samsung BioLogics as a result of the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. For additional information on the sale of our equity interest in Samsung Bioepis, please read Note 2, Dispositions, to these condensed consolidated financial statements. |
Summary of fair and carrying value of debt instruments | The fair and carrying values of our debt instruments, which are Level 2 liabilities, are summarized as follows: As of March 31, 2023 As of December 31, 2022 (In millions) Fair Carrying Fair Carrying 4.050% Senior Notes due September 15, 2025 $ 1,711.6 $ 1,745.2 $ 1,699.9 $ 1,744.7 2.250% Senior Notes due May 1, 2030 1,262.2 1,493.1 1,219.0 1,492.9 5.200% Senior Notes due September 15, 2045 1,130.2 1,100.4 1,033.2 1,100.3 3.150% Senior Notes due May 1, 2050 1,043.7 1,473.9 989.0 1,473.8 3.250% Senior Notes due February 15, 2051 493.2 470.1 469.1 469.3 Total $ 5,640.9 $ 6,282.7 $ 5,410.2 $ 6,281.0 |
Fair value of contingent consideration obligations | In connection with our acquisition of Convergence, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair value of our contingent consideration obligations, which were classified as Level 3 measurements: (In millions) For the three months ended March 31, 2022 Fair value, beginning of period $ 209.1 Changes in fair value (7.1) Fair value, end of period $ 202.0 |
Financial Instruments (Tables)
Financial Instruments (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Investments, Debt and Equity Securities [Abstract] | |
Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents | The following table summarizes our financial assets with maturities of less than 90 days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets: (In millions) As of March 31, 2023 As of December 31, 2022 Commercial paper $ 64.0 $ 177.2 Overnight reverse repurchase agreements 300.3 59.0 Money market funds 2,042.3 2,581.5 Short-term debt securities — 29.9 Total $ 2,406.6 $ 2,847.6 |
Marketable debt and equity securities | The following tables summarize our marketable debt and equity securities, classified as available-for-sale: As of March 31, 2023 (In millions) Amortized Gross Gross Fair Marketable debt securities Corporate debt securities: Current $ 1,287.6 $ 0.1 $ (4.4) $ 1,283.3 Non-current 423.4 1.0 (3.5) 420.9 Government securities: Current 863.5 0.1 (4.2) 859.4 Non-current 426.1 1.0 (1.5) 425.6 Mortgage and other asset backed securities: Current 0.4 — — 0.4 Non-current 132.9 0.1 (1.3) 131.7 Total marketable debt securities $ 3,133.9 $ 2.3 $ (14.9) $ 3,121.3 Marketable equity securities Marketable equity securities, current $ 87.7 $ — $ (19.8) $ 67.9 Marketable equity securities, non-current 1,001.1 — (390.9) 610.2 Total marketable equity securities $ 1,088.8 $ — $ (410.7) $ 678.1 As of December 31, 2022 (In millions) Amortized Gross Gross Fair Marketable debt securities Corporate debt securities: Current $ 936.2 $ — $ (4.9) $ 931.3 Non-current 305.3 0.1 (5.1) 300.3 Government securities: Current 547.1 0.1 (5.0) 542.2 Non-current 271.4 — (3.3) 268.1 Mortgage and other asset backed securities: Current — — — — Non-current 139.1 0.1 (1.9) 137.3 Total marketable debt securities $ 2,199.1 $ 0.3 $ (20.2) $ 2,179.2 Marketable equity securities Marketable equity securities, non-current $ 1,133.8 $ — $ (342.7) $ 791.1 Total marketable equity securities $ 1,133.8 $ — $ (342.7) $ 791.1 |
Summary of contractual maturities: available-for-sale securities | The estimated fair value and amortized cost of our marketable debt securities classified as available-for-sale by contractual maturity are summarized as follows: As of March 31, 2023 As of December 31, 2022 (In millions) Estimated Amortized Estimated Amortized Due in one year or less $ 2,143.1 $ 2,151.5 $ 1,473.5 $ 1,483.3 Due after one year through five years 962.2 965.8 694.4 703.7 Due after five years 16.0 16.6 11.3 12.1 Total marketable debt securities $ 3,121.3 $ 3,133.9 $ 2,179.2 $ 2,199.1 |
Proceeds from marketable debt securities | The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows: For the Three Months Ended March 31, (In millions) 2023 2022 Proceeds from maturities and sales $ 406.7 $ 543.6 Realized gains 0.1 — Realized losses 0.7 0.6 |
Derivative Instruments (Tables)
Derivative Instruments (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Foreign currency forward contracts that were entered into to hedge forecasted revenue | The notional amount of foreign currency forward contracts and foreign currency options that were entered into to hedge forecasted revenue and operating expense is summarized as follows: Notional Amount (In millions) As of March 31, 2023 As of December 31, 2022 Euro $ 1,854.8 $ 1,495.5 British pound 124.3 162.8 Swiss franc 248.2 — Canadian dollar 43.3 57.2 Total foreign currency contracts and options $ 2,270.6 $ 1,715.5 |
Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income | The following table summarizes the effect of foreign currency forward contracts and forward currency options designated as hedging instruments in our condensed consolidated statements of income: For the Three Months Ended March 31, Net Gains/(Losses) Net Gains/(Losses) Location 2023 2022 Location 2023 2022 Revenue $ 17.6 $ 20.9 Revenue $ 1.6 $ (6.5) Operating expense (0.5) (0.3) Operating expense (2.1) (0.1) |
Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income | The following table summarizes the effect of our net investment hedges in our condensed consolidated financial statements: For the Three Months Ended March 31, Net Gains/(Losses) Net Gains/(Losses) Net Gains/(Losses) Location 2022 Location 2022 Location 2022 Gains (losses) on net investment hedges (1) $ 10.1 Gains (losses) on net investment hedges (1) $ (3.3) Other (income) expense (1) $ (1.1) (1) Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read Note 2, Dispositions, to these condensed consolidated financial statements. |
Summary of fair value and presentation of derivatives | The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments: (In millions) Balance Sheet Location As of March 31, 2023 As of December 31, 2022 Cash Flow Hedging Instruments: Asset derivative instruments Other current assets $ 12.3 $ 37.9 Investments and other assets 0.1 — Liability derivative instruments Accrued expense and other 31.9 18.4 Other long-term liabilities 0.3 — Other Derivative Instruments: Asset derivative instruments Other current assets 22.7 25.1 Liability derivative instruments Accrued expense and other 7.6 7.6 |
Derivative Instruments, Unrealized Gain (Loss) | The pre-tax portion of the fair value of these foreign currency forward contracts and foreign currency options that were included in AOCI in total equity is summarized as follows: (In millions) As of March 31, 2023 As of December 31, 2022 Unrealized gains $ 8.8 $ 29.9 Unrealized (losses) (39.0) (21.3) Net unrealized gains (losses) $ (30.2) $ 8.6 |
Accumulated Other Comprehensive
Accumulated Other Comprehensive Income (Loss) (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Equity [Abstract] | |
Schedule of Accumulated Other Comprehensive Income (Loss) | The following tables summarize the changes in AOCI, net of tax by component: March 31, 2023 (In millions) Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax Currency Translation Adjustments Total Balance, December 31, 2022 $ (15.7) $ 15.1 $ (1.1) $ (163.2) $ (164.9) Other comprehensive income (loss) before reclassifications 5.3 (20.3) 0.5 22.1 7.6 Amounts reclassified from AOCI 0.4 (15.1) — — (14.7) Net current period other comprehensive income (loss) 5.7 (35.4) 0.5 22.1 (7.1) Balance, March 31, 2023 $ (10.0) $ (20.3) $ (0.6) $ (141.1) $ (172.0) March 31, 2022 (In millions) Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax Gains (Losses) on Net Investment Hedges, Net of Tax (1) Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax Currency Translation Adjustments Total Balance, December 31, 2021 $ (2.2) $ 53.8 $ 25.5 $ (44.8) $ (139.0) $ (106.7) Other comprehensive income (loss) before reclassifications (10.2) 34.4 5.1 0.9 (21.8) 8.4 Amounts reclassified from AOCI 0.5 (18.5) 1.1 — — (16.9) Net current period other comprehensive income (loss) (9.7) 15.9 6.2 0.9 (21.8) (8.5) Balance, March 31, 2022 $ (11.9) $ 69.7 $ 31.7 $ (43.9) $ (160.8) $ (115.2) (1) Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read Note 2, Dispositions, to these condensed consolidated financial statements. |
Reclassification out of Accumulated Other Comprehensive Income | The following table summarizes the amounts reclassified from AOCI: (In millions) Amounts Reclassified from AOCI Income Statement Location For the Three Months Ended March 31, 2023 2022 Gains (losses) on securities available for sale $ (0.5) $ (0.6) Other (income) expense 0.1 0.1 Income tax (benefit) expense Gains (losses) on cash flow hedges 17.6 20.9 Revenue (0.5) (0.3) Operating expense (0.1) (0.1) Other (income) expense (1.9) (2.0) Income tax (benefit) expense Gains (losses) on net investment hedges (1) — (1.1) Other (income) expense Total reclassifications, net of tax $ 14.7 $ 16.9 (1) Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read Note 2, Dispositions, to these condensed consolidated financial statements. |
Earnings per Share (Tables)
Earnings per Share (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Earnings Per Share [Abstract] | |
Basic and diluted earnings per share | Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows: For the Three Months Ended March 31, (In millions) 2023 2022 Numerator: Net income attributable to Biogen Inc. $ 387.9 $ 303.8 Denominator: Weighted average number of common shares outstanding 144.4 147.1 Effect of dilutive securities: Time-vested restricted stock units 0.6 0.3 Market stock units 0.1 0.1 Performance stock units settled in stock 0.1 0.1 Dilutive potential common shares 0.8 0.5 Shares used in calculating diluted earnings per share 145.2 147.6 |
Share-Based Payments (Tables)
Share-Based Payments (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
Share-based compensation expense included in condensed consolidated statements of income | The following table summarizes share-based compensation expense included in our condensed consolidated statements of income: For the Three Months Ended March 31, (In millions) 2023 2022 Research and development $ 31.3 $ 25.7 Selling, general and administrative 50.1 46.1 Subtotal 81.4 71.8 Capitalized share-based compensation costs (3.3) (2.8) Share-based compensation expense included in total cost and expense 78.1 69.0 Income tax effect (14.7) (12.8) Share-based compensation expense included in net income attributable to Biogen Inc. $ 63.4 $ 56.2 |
Summary of share-based compensation expense associated with each of our share-based compensating programs | The following table summarizes share-based compensation expense associated with each of our share-based compensation programs: For the Three Months Ended March 31, (In millions) 2023 2022 Market stock units $ 2.2 $ 5.9 Time-vested restricted stock units 61.7 51.3 Performance stock units settled in stock 9.5 8.3 Performance stock units settled in cash 2.5 1.4 Employee stock purchase plan 4.7 4.9 Stock options (1) 0.8 — Subtotal 81.4 71.8 Capitalized share-based compensation costs (3.3) (2.8) Share-based compensation expense included in total cost and expense $ 78.1 $ 69.0 (1) During the fourth quarter of 2022 we granted stock options. For additional information, please read Note 16, Share-Based Payments , to our consolidated financial statements included in our 2022 Form 10-K. |
Income Taxes (Tables)
Income Taxes (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
Reconciliation between the U.S. federal statutory tax rate and effective tax rate | A reconciliation between the U.S. federal statutory tax rate and our effective tax rate is summarized as follows: For the Three Months Ended March 31, 2023 2022 Statutory rate 21.0 % 21.0 % State taxes 1.3 (0.4) Taxes on foreign earnings (5.6) (10.8) Tax credits (6.6) (2.5) Purchased intangible assets 0.4 0.6 GILTI 0.5 0.3 Neurimmune tax impacts — 24.2 Other 0.6 3.8 Effective tax rate 11.6 % 36.2 % |
Other Consolidated Financial _2
Other Consolidated Financial Statement Detail (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Other income (expense), net | Components of other (income) expense, net, are summarized as follows: For the Three Months Ended March 31, (In millions) 2023 2022 Interest income $ (80.9) $ (2.9) Interest expense 62.5 66.1 (Gains) losses on investments, net 77.7 191.1 Foreign exchange (gains) losses, net 10.7 8.3 Other, net (0.6) 0.7 Total other (income) expense, net $ 69.4 $ 263.3 |
Gain (loss) on investments in equity securities | The following table summarizes our (gains) losses on investments, net that relate to our equity securities held during the following periods: For the Three Months Ended March 31, (In millions) 2023 2022 Net (gains) losses recognized on equity securities $ 78.1 $ 190.7 Less: Net (gains) losses realized on equity securities 1.6 (0.2) Net unrealized (gains) losses recognized on equity securities $ 76.5 $ 190.9 The net unrealized losses recognized during the three months ended March 31, 2023, primarily reflect a decrease in the aggregate fair value of our investments in Denali, Sangamo and Ionis common stock of approximately $100.0 million, partially offset by an increase in the fair value of Sage common stock of approximately $23.8 million. The net unrealized losses recognized during the three months ended March 31, 2022, primarily reflect a decrease in the aggregate fair value of our investments in Denali, Sage and Sangamo common stock of approximately $205.5 million, partially offset by an increase in the fair value of Ionis common stock of approximately $19.0 million. |
Accrued expenses and other | Accrued expense and other consists of the following: (In millions) As of March 31, 2023 As of December 31, 2022 Revenue-related reserves for discounts and allowances $ 907.2 $ 891.6 Employee compensation and benefits 187.2 395.6 Collaboration expense 265.5 277.9 Royalties and licensing fees 183.9 209.4 Other 744.4 746.9 Total accrued expense and other $ 2,288.2 $ 2,521.4 |
Collaborative and Other Relat_2
Collaborative and Other Relationships (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Co-promotion profit sharing formula | As a result of the FDA approval of LUNSUMIO our share of the combined annual co-promotion profits for RITUXAN and LUNSUMIO in excess of $50.0 million varies upon the following events, as summarized in the table below: After LUNSUMIO Approval until the First Threshold Date 37.5 % After First Threshold Date until the Second Threshold Date 35.0 % After Second Threshold Date 30.0 % |
Pretax profit sharing formula | Our share of annual co-promotion profits in excess of $50.0 million varies upon the following events, as summarized in the table below: Until Second GAZYVA Threshold Date 37.5 % After Second GAZYVA Threshold Date 35.0 % |
Revenues from anti-CD20 therapeutic programs | Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN. For the Three Months Ended March 31, (In millions) 2023 2022 Royalty revenue on sales of OCREVUS $ 283.6 $ 252.3 Biogen’s share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO 112.5 143.2 Other revenue from anti-CD20 therapeutic programs 3.4 3.9 Total revenue from anti-CD20 therapeutic programs $ 399.5 $ 399.4 |
Summary of activity related to Aducanumab collaboration | A summary of development expense and sales and marketing expense related to our initial ADUHELM Collaboration Agreement is as follows: For the Three Months Ended March 31, (In millions) 2022 Total ADUHELM Collaboration development expense $ 44.2 Biogen's share of ADUHELM Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income 24.3 Total sales and marketing expense incurred by the ADUHELM Collaboration Agreement 95.0 Biogen's share of ADUHELM Collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income 50.9 |
Summary of activity related to the UCB collaboration | A summary of development expense related to the UCB collaboration agreement is as follows: For the Three Months Ended March 31, (In millions) 2023 2022 Total UCB collaboration development expense $ 18.3 $ 17.6 Biogen's share of UCB collaboration development expense reflected in research and development expense in our condensed consolidated statements of income 9.2 8.8 |
Summary of Activity Related to Denali Therapeutics Collaboration | A summary of development expense related to this collaboration is as follows: For the Three Months Ended March 31, (In millions) 2023 2022 Total Denali collaboration development expense $ 16.6 $ 14.9 Biogen's share of Denali collaboration development expense reflected in research and development expense in our condensed consolidated statements of income 10.0 8.9 |
Summary of Activity Related to BAN2401 and Elenbecestat Collaboration | For the Three Months Ended March 31, (In millions) 2023 2022 Total development expense incurred by the collaboration related to the advancement of LEQEMBI $ 107.9 $ 77.0 Biogen's share of the LEQEMBI Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income 54.0 38.5 Total sales and marketing expense incurred by the LEQEMBI Collaboration (1) 10.5 15.9 Biogen's share of the LEQEMBI Collaboration sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income (1) 5.3 8.0 (1) Beginning in the first quarter of 2023 reimbursement to Eisai for our share of U.S. LEQEMBI selling, general and administrative expense is recognized in revenue from LEQEMBI Collaboration within our condensed consolidated statements of income. |
Summary of Activity Related to Sangamo Therapeutics | A summary of development expense related to this collaboration is as follows: For the Three Months Ended March 31, (In millions) 2023 2022 Total Sangamo collaboration development expense $ 5.1 $ 8.3 Biogen's share of Sangamo collaboration development expense reflected in research and development expense in our condensed consolidated statements of income 2.3 5.5 |
Summary of Activity Related to Sage Therapeutics | A summary of development and sales and marketing expense related to this collaboration is as follows: For the Three Months Ended March 31, (In millions) 2023 2022 Total Sage collaboration development expense $ 34.8 $ 38.7 Biogen's share of Sage collaboration development expense reflected in research and development expense in our condensed consolidated statements of income 17.4 19.4 Total Sage sales and marketing expense incurred by the collaboration 38.2 18.4 Biogen's share of Sage collaboration sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income 19.1 9.2 |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Details) | 3 Months Ended |
Mar. 31, 2023 segment | |
Accounting Policies [Abstract] | |
Number of reportable segments | 1 |
Interest in subsidiary (less than given percentage) | 100% |
Dispositions (Details Textual)
Dispositions (Details Textual) ₩ in Millions, $ in Millions | 1 Months Ended | 3 Months Ended | |||
Apr. 30, 2022 USD ($) | Mar. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2022 KRW (₩) | Mar. 31, 2022 | |
Samsung Bioepis | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Equity, ownership interest | 49.90% | 49.90% | |||
Samsung Bioepis | Fair Value, Recurring | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Other current assets, receivable | $ 809.9 | $ 798.8 | |||
Other assets, receivable | $ 411.6 | $ 405.4 | |||
Samsung Bioepis | Payment Due At First Anniversary | Discount rates | Fair Value, Recurring | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Risk-adjusted discount rates | 0.059 | ||||
Samsung Bioepis | Payment Due At Second Anniversary | Discount rates | Fair Value, Recurring | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Risk-adjusted discount rates | 0.058 | ||||
Samsung Bioepis | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Proceeds from divestiture of interest in joint venture | $ 1,000 | ||||
Payables to divestiture of interest in joint venture | 1,300 | ||||
Gain on sale of equity interest in Samsung Bioepis | $ 1,500 | ||||
Cumulative translation loss | 58.9 | ||||
Gain on derivative used in net investment hedge | 57 | ||||
Additional milestone payment | 50 | ||||
Investment in Samsung Bioepis | ₩ | ₩ 581.6 | ||||
Samsung Bioepis | Payment Due At First Anniversary | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Payables to divestiture of interest in joint venture | 812.5 | ||||
Gain (loss) on sale | 11.1 | ||||
Samsung Bioepis | Payment Due At Second Anniversary | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Payables to divestiture of interest in joint venture | $ 437.5 | ||||
Gain (loss) on sale | $ (6.2) |
Restructuring, Business Trans_3
Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details) - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended | |
Sep. 30, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | |
Restructuring Cost and Reserve [Line Items] | |||
Restructuring charges | $ 9.6 | $ 38.1 | |
Employee related costs | 7.1 | $ 27.7 | |
Gain due to lease termination | $ 5.3 | ||
Accelerated depreciation expense | 10.4 | ||
Other restructuring costs | 2.5 | ||
Minimum | |||
Restructuring Cost and Reserve [Line Items] | |||
Restructuring charges | $ 135 |
Restructuring, Business Trans_4
Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Restructuring Cost and Reserve [Line Items] | ||
Expense | $ 9.6 | $ 38.1 |
Foreign currency and other adjustments | 0.6 | 0 |
Workforce Reduction | ||
Restructuring Cost and Reserve [Line Items] | ||
Restructuring reserve, beginning | 35.9 | 0 |
Expense | 7.1 | 27.7 |
Payment | (15.6) | (6.2) |
Restructuring reserve, ending | $ 28 | $ 21.5 |
Revenues - Revenues by product
Revenues - Revenues by product (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Disaggregation of Revenue [Line Items] | ||
Product revenues | $ 2,463 | $ 2,531.8 |
MS Product Revenues | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 1,125.2 | 1,394.5 |
MS Product Revenues | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 546.1 | 709.1 |
MS Product Revenues | Rest of World | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 579.1 | 685.4 |
Fumarate | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 382.7 | 537.9 |
Fumarate | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 168.2 | 242.3 |
Fumarate | Rest of World | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 214.5 | 295.6 |
TECFIDERA | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 274.5 | 409.9 |
TECFIDERA | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 74.7 | 117.1 |
TECFIDERA | Rest of World | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 199.8 | 292.8 |
VUMERITY | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 108.2 | 128 |
VUMERITY | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 93.5 | 125.2 |
VUMERITY | Rest of World | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 14.7 | 2.8 |
Interferon | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 245.6 | 309.6 |
Interferon | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 132.5 | 182.3 |
Interferon | Rest of World | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 113.1 | 127.3 |
AVONEX | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 172.4 | 229.6 |
AVONEX | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 102.6 | 148 |
AVONEX | Rest of World | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 69.8 | 81.6 |
PLEGRIDY | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 73.2 | 80 |
PLEGRIDY | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 29.9 | 34.3 |
PLEGRIDY | Rest of World | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 43.3 | 45.7 |
TYSABRI | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 472.8 | 520.8 |
TYSABRI | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 245.4 | 284.5 |
TYSABRI | Rest of World | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 227.4 | 236.3 |
FAMPYRA | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 24.1 | 26.2 |
FAMPYRA | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 0 | 0 |
FAMPYRA | Rest of World | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 24.1 | 26.2 |
SPINRAZA | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 443.3 | 472.5 |
SPINRAZA | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 146.7 | 163.3 |
SPINRAZA | Rest of World | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 296.6 | 309.2 |
Biosimilars | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 192.4 | 194.3 |
Biosimilars | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 8.2 | 0 |
Biosimilars | Rest of World | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 184.2 | 194.3 |
BENEPALI | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 109 | 114.7 |
BENEPALI | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 0 | 0 |
BENEPALI | Rest of World | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 109 | 114.7 |
IMRALDI | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 54.4 | 57.1 |
IMRALDI | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 0 | 0 |
IMRALDI | Rest of World | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 54.4 | 57.1 |
FLIXABI | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 20.4 | 22.5 |
FLIXABI | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 0 | 0 |
FLIXABI | Rest of World | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 20.4 | 22.5 |
BYOOVIZ | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 8.6 | 0 |
BYOOVIZ | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 8.2 | 0 |
BYOOVIZ | Rest of World | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 0.4 | 0 |
Product, net | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 1,763.3 | 2,066.3 |
Product, net | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 701.4 | 875.2 |
Product, net | Rest of World | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 1,061.9 | 1,191.1 |
FUMADERM And ADUHELM | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 2.4 | 5 |
FUMADERM And ADUHELM | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | 0.4 | 2.8 |
FUMADERM And ADUHELM | Rest of World | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | $ 2 | $ 2.2 |
Revenues Reserves for Discounts
Revenues Reserves for Discounts and Allowances (Details 1) $ in Millions | 3 Months Ended |
Mar. 31, 2023 USD ($) | |
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] | |
Beginning Balance | $ 1,035 |
Current Provisions Relating To Sales In Current Year | 823.8 |
Adjustments Relating To Prior Years | (8.2) |
Payments/Returns Relating To Sales in Current Year | (356.8) |
Payments/Returns Relating To Sales in Prior Year | (448.8) |
Ending Balance | 1,045 |
Discounts | |
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] | |
Beginning Balance | 153.8 |
Current Provisions Relating To Sales In Current Year | 182.3 |
Adjustments Relating To Prior Years | (1.1) |
Payments/Returns Relating To Sales in Current Year | (94) |
Payments/Returns Relating To Sales in Prior Year | (73.3) |
Ending Balance | 167.7 |
Contractual adjustments | |
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] | |
Beginning Balance | 857.7 |
Current Provisions Relating To Sales In Current Year | 638 |
Adjustments Relating To Prior Years | (8.1) |
Payments/Returns Relating To Sales in Current Year | (261.8) |
Payments/Returns Relating To Sales in Prior Year | (368.1) |
Ending Balance | 857.7 |
Returns | |
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] | |
Beginning Balance | 23.5 |
Current Provisions Relating To Sales In Current Year | 3.5 |
Adjustments Relating To Prior Years | 1 |
Payments/Returns Relating To Sales in Current Year | (1) |
Payments/Returns Relating To Sales in Prior Year | (7.4) |
Ending Balance | $ 19.6 |
Revenues- Reserves for Discount
Revenues- Reserves for Discounts and Allowances (Details 2) - USD ($) $ in Millions | Mar. 31, 2023 | Dec. 31, 2022 |
Total Reserves | $ 1,045 | $ 1,035 |
Reduction of accounts receivable | ||
Total Reserves | 137.8 | 143.4 |
Component of accrued expenses and other | ||
Total Reserves | $ 907.2 | $ 891.6 |
Revenues - Revenues from Anti-C
Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Disaggregation of Revenue [Line Items] | ||
Total revenues from anti-CD20 therapeutic programs | $ 2,463 | $ 2,531.8 |
Genentech | ||
Disaggregation of Revenue [Line Items] | ||
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA | 112.5 | 143.2 |
Other revenues from anti-CD20 therapeutic programs | 3.4 | 3.9 |
Revenue from anti-CD20 therapeutic programs | ||
Disaggregation of Revenue [Line Items] | ||
Total revenues from anti-CD20 therapeutic programs | 399.5 | 399.4 |
Royalty Attributed To OCREVUS | ||
Disaggregation of Revenue [Line Items] | ||
Total revenues from anti-CD20 therapeutic programs | $ 283.6 | $ 252.3 |
Revenues - Other Revenues (Deta
Revenues - Other Revenues (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Disaggregation of Revenue [Line Items] | ||
Total revenue | $ 2,463 | $ 2,531.8 |
Contract manufacturing and other revenue | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 306.9 | 47.5 |
Royalty | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 12.2 | 18.6 |
Contract manufacturing, royalty and other revenue | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | $ 319.1 | $ 66.1 |
Revenues - Narrative (Details)
Revenues - Narrative (Details) $ in Millions | 3 Months Ended | |
Mar. 31, 2023 USD ($) wholesaler | Mar. 31, 2022 USD ($) | |
Disaggregation of Revenue [Line Items] | ||
Number of wholesalers | wholesaler | 2 | |
Product revenues | $ 2,463 | $ 2,531.8 |
Distributor One | ||
Disaggregation of Revenue [Line Items] | ||
Percentage of revenues from major distributors | 27.30% | 26.30% |
Distributor Two | ||
Disaggregation of Revenue [Line Items] | ||
Percentage of revenues from major distributors | 7.40% | 10.50% |
Contract manufacturing, royalty and other revenue | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | $ 319.1 | $ 66.1 |
LEQEMBI Collaboration | ||
Disaggregation of Revenue [Line Items] | ||
Product revenues | $ (18.9) | $ 0 |
Inventory - Components of Inven
Inventory - Components of Inventory (Details) - USD ($) $ in Millions | Mar. 31, 2023 | Dec. 31, 2022 |
Inventory Disclosure [Abstract] | ||
Raw materials | $ 432.4 | $ 413.2 |
Work in process | 684.9 | 751.9 |
Finished goods | 205.9 | 200.4 |
Inventory | 1,323.2 | 1,365.5 |
Inventory, current | 1,281 | 1,344.4 |
Inventory, noncurrent | $ 42.2 | $ 21.1 |
Inventory - Narrative (Details)
Inventory - Narrative (Details) - USD ($) $ in Millions | 3 Months Ended | ||
Mar. 31, 2023 | Dec. 31, 2022 | Mar. 31, 2022 | |
Inventory [Line Items] | |||
Excess and obsolescence charges related to inventory | $ 17.4 | $ 281.5 | |
(Gain) loss on equity method investments | $ 0 | $ (3.3) | |
Percentage of future development costs related to Eisai | 45% | ||
Inventory | $ 1,323.2 | $ 1,365.5 | |
Eisai | |||
Inventory [Line Items] | |||
Percentage of future development costs related to Eisai | 45% | ||
ADUHELM | |||
Inventory [Line Items] | |||
Excess and obsolescence charges related to inventory | $ 275 | $ 275 | |
ADUHELM | Eisai | Centers for Medicare and Medicaid Service | |||
Inventory [Line Items] | |||
(Gain) loss on equity method investments | $ 136 |
Intangible Assets and Goodwil_2
Intangible Assets and Goodwill (Details) - USD ($) $ in Millions | 3 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2022 | |
Intangible assets | |||
Total intangible assets, gross | $ 7,492.7 | $ 7,479.3 | |
Accumulated Amortization | (5,679.4) | (5,629.2) | |
Intangible assets, net | 1,813.3 | 1,850.1 | |
Amortization and impairment of acquired intangible assets | 50.2 | $ 66.9 | |
Expected future amortization expense, 2023 (remaining three months) | 165 | ||
Expected future amortization expense, 2024 | 195 | ||
Expected future amortization expense, 2025 | 190 | ||
Expected future amortization expense, 2026 | 175 | ||
Expected future amortization expense, 2027 | 170 | ||
Expected future amortization expense, 2028 | 165 | ||
Completed technology | |||
Intangible assets | |||
Cost | 7,428.7 | 7,415.3 | |
Net | 1,749.3 | 1,786.1 | |
Accumulated Amortization | $ (5,679.4) | (5,629.2) | |
Completed technology | Minimum | |||
Intangible assets | |||
Useful life | 4 years | ||
Completed technology | Maximum | |||
Intangible assets | |||
Useful life | 28 years | ||
Trademarks and Trade Names | |||
Intangible assets | |||
Cost and Net | $ 64 | 64 | |
Accumulated Amortization | 0 | 0 | |
Indefinite-lived Intangible Assets (Excluding Goodwill) | $ 64 | $ 64 |
Intangible Assets and Goodwil_3
Intangible Assets and Goodwill (Details 1) | 3 Months Ended |
Mar. 31, 2023 USD ($) | |
Summary of roll forward of the changes in goodwill | |
Goodwill, beginning of period | $ 5,749,000,000 |
Other | 2,800,000 |
Goodwill, end of period | 5,751,800,000 |
Accumulated impairment losses related to goodwill | $ 0 |
Fair Value Measurements (Detail
Fair Value Measurements (Details) - USD ($) $ in Millions | Mar. 31, 2023 | Dec. 31, 2022 | Mar. 31, 2022 | Dec. 31, 2021 |
Assets: | ||||
Marketable debt securities | $ 3,121.3 | $ 2,179.2 | ||
Samsung Bioepis | ||||
Liabilities: | ||||
Equity, ownership interest | 49.90% | 49.90% | ||
Fair Value, Measurements Recurring | ||||
Assets: | ||||
Cash equivalents | $ 2,406.6 | 2,847.6 | ||
Marketable equity securities | 678.1 | 791.1 | ||
Derivative contracts | 35.1 | 63 | ||
Plan assets for deferred compensation | 34.1 | 32.8 | ||
Total | 7,496.7 | 7,117.9 | ||
Liabilities: | ||||
Derivative contracts | 39.8 | 26 | ||
Contingent consideration obligations | $ 202 | $ 209.1 | ||
Total | 39.8 | 26 | ||
Fair Value, Measurements Recurring | Samsung Bioepis | ||||
Assets: | ||||
Other current assets, receivable | 809.9 | 798.8 | ||
Other assets, receivable | 411.6 | 405.4 | ||
Fair Value, Measurements Recurring | Corporate debt securities | ||||
Assets: | ||||
Marketable debt securities | 1,704.2 | 1,231.6 | ||
Fair Value, Measurements Recurring | Government securities | ||||
Assets: | ||||
Marketable debt securities | 1,285 | 810.3 | ||
Fair Value, Measurements Recurring | Mortgage and other asset backed securities | ||||
Assets: | ||||
Marketable debt securities | 132.1 | 137.3 | ||
Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements Recurring | ||||
Assets: | ||||
Cash equivalents | 0 | 0 | ||
Marketable equity securities | 678.1 | 791.1 | ||
Derivative contracts | 0 | 0 | ||
Plan assets for deferred compensation | 0 | 0 | ||
Total | 678.1 | 791.1 | ||
Liabilities: | ||||
Derivative contracts | 0 | 0 | ||
Total | 0 | 0 | ||
Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements Recurring | Samsung Bioepis | ||||
Assets: | ||||
Other current assets, receivable | 0 | 0 | ||
Other assets, receivable | 0 | 0 | ||
Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements Recurring | Corporate debt securities | ||||
Assets: | ||||
Marketable debt securities | 0 | 0 | ||
Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements Recurring | Government securities | ||||
Assets: | ||||
Marketable debt securities | 0 | 0 | ||
Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements Recurring | Mortgage and other asset backed securities | ||||
Assets: | ||||
Marketable debt securities | 0 | 0 | ||
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements Recurring | ||||
Assets: | ||||
Cash equivalents | 2,406.6 | 2,847.6 | ||
Marketable equity securities | 0 | 0 | ||
Derivative contracts | 35.1 | 63 | ||
Plan assets for deferred compensation | 34.1 | 32.8 | ||
Total | 5,597.1 | 5,122.6 | ||
Liabilities: | ||||
Derivative contracts | 39.8 | 26 | ||
Total | 39.8 | 26 | ||
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements Recurring | Samsung Bioepis | ||||
Assets: | ||||
Other current assets, receivable | 0 | 0 | ||
Other assets, receivable | 0 | 0 | ||
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements Recurring | Corporate debt securities | ||||
Assets: | ||||
Marketable debt securities | 1,704.2 | 1,231.6 | ||
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements Recurring | Government securities | ||||
Assets: | ||||
Marketable debt securities | 1,285 | 810.3 | ||
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements Recurring | Mortgage and other asset backed securities | ||||
Assets: | ||||
Marketable debt securities | 132.1 | 137.3 | ||
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements Recurring | ||||
Assets: | ||||
Cash equivalents | 0 | 0 | ||
Marketable equity securities | 0 | 0 | ||
Derivative contracts | 0 | 0 | ||
Plan assets for deferred compensation | 0 | 0 | ||
Total | 1,221.5 | 1,204.2 | ||
Liabilities: | ||||
Derivative contracts | 0 | 0 | ||
Total | 0 | 0 | ||
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements Recurring | Samsung Bioepis | ||||
Assets: | ||||
Other current assets, receivable | 809.9 | 798.8 | ||
Other assets, receivable | 411.6 | 405.4 | ||
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements Recurring | Corporate debt securities | ||||
Assets: | ||||
Marketable debt securities | 0 | 0 | ||
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements Recurring | Government securities | ||||
Assets: | ||||
Marketable debt securities | 0 | 0 | ||
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements Recurring | Mortgage and other asset backed securities | ||||
Assets: | ||||
Marketable debt securities | $ 0 | $ 0 |
Fair Value Measurements (Deta_2
Fair Value Measurements (Details Textual) | 3 Months Ended |
Mar. 31, 2023 USD ($) | |
Fair Value Disclosures [Abstract] | |
Asset impairment charges | $ 0 |
Fair Value Measurements (Deta_3
Fair Value Measurements (Details 1) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2023 | Dec. 31, 2022 | |
Debt Instrument [Line Items] | ||
Notes Payable | $ 6,282.7 | $ 6,281 |
Debt Instrument, Fair Value Disclosure | 5,640.9 | 5,410.2 |
BIIB054 | ||
Debt Instrument [Line Items] | ||
Reduction in contingent consideration | 195.4 | |
4.050% Senior Notes due 2025 | ||
Debt Instrument [Line Items] | ||
Notes payable, fair value | 1,711.6 | 1,699.9 |
Notes Payable | 1,745.2 | 1,744.7 |
2.250% Senior Notes due May 1, 2030 | ||
Debt Instrument [Line Items] | ||
Notes payable, fair value | 1,130.2 | 1,033.2 |
Notes Payable | 1,100.4 | 1,100.3 |
5.200% Senior Notes due 2045 | ||
Debt Instrument [Line Items] | ||
Notes payable, fair value | 1,262.2 | 1,219 |
Notes Payable | 1,493.1 | 1,492.9 |
3.250% Senior Notes, Due February 15, 2051 | ||
Debt Instrument [Line Items] | ||
Notes payable, fair value | 493.2 | 469.1 |
Notes Payable | 470.1 | 469.3 |
3.150% Senior Notes due May 1, 2050 | ||
Debt Instrument [Line Items] | ||
Notes payable, fair value | 1,043.7 | 989 |
Notes Payable | $ 1,473.9 | $ 1,473.8 |
Fair Value Measurements (Deta_4
Fair Value Measurements (Details 2) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Business Acquisition, Contingent Consideration [Line Items] | ||
Contingent consideration impairment | $ 0 | $ 7.1 |
Fair Value, Measurements Recurring | ||
Business Acquisition, Contingent Consideration [Line Items] | ||
Fair value, beginning of period | 209.1 | |
Fair value, end of period | $ 202 |
Financial Instruments (Details)
Financial Instruments (Details) - USD ($) $ in Millions | Mar. 31, 2023 | Dec. 31, 2022 |
Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents | ||
Cash equivalents | $ 2,406.6 | $ 2,847.6 |
Commercial paper | ||
Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents | ||
Cash equivalents | 64 | 177.2 |
Overnight reverse repurchase agreements | ||
Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents | ||
Cash equivalents | 300.3 | 59 |
Money market funds | ||
Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents | ||
Cash equivalents | 2,042.3 | 2,581.5 |
Short-term debt securities | ||
Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents | ||
Cash equivalents | $ 0 | $ 29.9 |
Financial Instruments (Details
Financial Instruments (Details 1) - USD ($) $ in Millions | Mar. 31, 2023 | Dec. 31, 2022 |
Marketable debt securities | ||
Amortized Cost | $ 3,133.9 | $ 2,199.1 |
Gross unrealized gains | 2.3 | 0.3 |
Gross unrealized losses | (14.9) | (20.2) |
Fair value | 3,121.3 | 2,179.2 |
Marketable equity securities | ||
Amortized Cost | 1,088.8 | 1,133.8 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | (410.7) | (342.7) |
Fair Value | 678.1 | 791.1 |
Corporate debt securities Current | ||
Marketable debt securities | ||
Amortized Cost | 1,287.6 | 936.2 |
Gross unrealized gains | 0.1 | 0 |
Gross unrealized losses | (4.4) | (4.9) |
Fair value | 1,283.3 | 931.3 |
Corporate debt securities Non-current | ||
Marketable debt securities | ||
Amortized Cost | 423.4 | 305.3 |
Gross unrealized gains | 1 | 0.1 |
Gross unrealized losses | (3.5) | (5.1) |
Fair value | 420.9 | 300.3 |
Government securities Current | ||
Marketable debt securities | ||
Amortized Cost | 863.5 | 547.1 |
Gross unrealized gains | 0.1 | 0.1 |
Gross unrealized losses | (4.2) | (5) |
Fair value | 859.4 | 542.2 |
Government securities Non-current | ||
Marketable debt securities | ||
Amortized Cost | 426.1 | 271.4 |
Gross unrealized gains | 1 | 0 |
Gross unrealized losses | (1.5) | (3.3) |
Fair value | 425.6 | 268.1 |
Mortgage and other asset backed securities Current | ||
Marketable debt securities | ||
Amortized Cost | 0.4 | 0 |
Gross unrealized gains | 0 | 0 |
Gross unrealized losses | 0 | 0 |
Fair value | 0.4 | 0 |
Mortgage and other asset backed securities Non-current | ||
Marketable debt securities | ||
Amortized Cost | 132.9 | 139.1 |
Gross unrealized gains | 0.1 | 0.1 |
Gross unrealized losses | (1.3) | (1.9) |
Fair value | 131.7 | 137.3 |
Equity Securities, Current | ||
Marketable equity securities | ||
Amortized Cost | 87.7 | 1,133.8 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | (19.8) | (342.7) |
Fair Value | 67.9 | $ 791.1 |
Equity Securities, Non-Current | ||
Marketable equity securities | ||
Amortized Cost | 1,001.1 | |
Gross Unrealized Gains | 0 | |
Gross Unrealized Losses | (390.9) | |
Fair Value | $ 610.2 |
Financial Instruments (Detail_2
Financial Instruments (Details 2) - USD ($) $ in Millions | Mar. 31, 2023 | Dec. 31, 2022 |
Summary of Contractual Maturities: Available-for-Sale Securities | ||
Due in one year or less, amortized cost | $ 2,151.5 | $ 1,483.3 |
Due in one year or less, estimated fair value | 2,143.1 | 1,473.5 |
Due after one year through five years, amortized cost | 965.8 | 703.7 |
Due after one year through five years, estimated fair value | 962.2 | 694.4 |
Due after five years, amortized cost | 16.6 | 12.1 |
Due after five years, estimated fair value | 16 | 11.3 |
Marketable debt securities | 3,121.3 | 2,179.2 |
Amortized Cost | $ 3,133.9 | $ 2,199.1 |
Financial Instruments (Detail_3
Financial Instruments (Details 3) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Investments, Debt and Equity Securities [Abstract] | ||
Proceeds from maturities and sales | $ 406.7 | $ 543.6 |
Realized gains | 0.1 | 0 |
Realized losses | $ 0.7 | $ 0.6 |
Financial Instruments (Detail_4
Financial Instruments (Details Textual) | 3 Months Ended | 9 Months Ended |
Mar. 31, 2023 | Sep. 30, 2022 | |
Investments, Debt and Equity Securities [Abstract] | ||
Average maturity of marketable securities, months | 9 months | 8 months |
Financial Instruments Financial
Financial Instruments Financial Instruments (Details Textual 2) - USD ($) $ in Millions | Mar. 31, 2023 | Dec. 31, 2022 |
Other noncurrent assets | Strategic Investments | ||
Business Acquisition [Line Items] | ||
Strategic investment portfolio | $ 733.6 | $ 846 |
Derivative Instruments (Details
Derivative Instruments (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2022 | May 31, 2018 | |
Derivatives [Line Items] | ||||
Gain (loss) on foreign currency derivative instruments not designated as hedging instruments | $ (1.8) | $ (12.2) | ||
Gains (losses) on net investment hedges, net of tax | $ 0 | 6.2 | ||
Minimum | ||||
Derivatives [Line Items] | ||||
Range of durations of foreign currency forward contracts | 1 month | 1 month | ||
Maximum | ||||
Derivatives [Line Items] | ||||
Range of durations of foreign currency forward contracts | 18 months | 12 months | ||
Not designated as hedging instrument | ||||
Derivatives [Line Items] | ||||
Derivative, Notional Amount | $ 1,436.3 | $ 1,238.8 | ||
Other current assets | Designated as hedging instrument | ||||
Derivatives [Line Items] | ||||
Derivative asset, fair value | 12.3 | 37.9 | ||
Other current assets | Not designated as hedging instrument | ||||
Derivatives [Line Items] | ||||
Derivative asset, fair value | 22.7 | 25.1 | ||
Other noncurrent assets | Designated as hedging instrument | ||||
Derivatives [Line Items] | ||||
Derivative asset, fair value | 0.1 | 0 | ||
Accrued expenses and other | Designated as hedging instrument | ||||
Derivatives [Line Items] | ||||
Derivative liability, fair value | 31.9 | 18.4 | ||
Accrued expenses and other | Not designated as hedging instrument | ||||
Derivatives [Line Items] | ||||
Derivative liability, fair value | 7.6 | 7.6 | ||
Foreign exchange contract | Designated as hedging instrument | ||||
Derivatives [Line Items] | ||||
Derivative, Notional Amount | 2,270.6 | 1,715.5 | ||
Foreign Exchange Forward | ||||
Derivatives [Line Items] | ||||
Unrealized Gain on Derivatives | 8.8 | 29.9 | ||
Unrealized Loss on Derivatives | (39) | (21.3) | ||
Unrealized Gain (Loss) on Derivatives | (30.2) | 8.6 | ||
Net Investment Hedging | ||||
Derivatives [Line Items] | ||||
Gains (losses) on net investment hedges, net of tax | 10.1 | |||
Gains (losses) on net investment hedge, excluded component | (3.3) | |||
Cash Flow Hedging [Member] | Foreign exchange contract | Other long-term liabilities | ||||
Derivatives [Line Items] | ||||
Derivative liability, fair value | 0.3 | 0 | ||
Revenue | Foreign exchange contract | ||||
Derivatives [Line Items] | ||||
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax | 17.6 | 20.9 | ||
Revenue | Cash flows, revenue | Foreign exchange contract | ||||
Derivatives [Line Items] | ||||
Gain on interest rate swap | 1.6 | (6.5) | ||
Operating expense | Foreign exchange contract | ||||
Derivatives [Line Items] | ||||
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax | (0.5) | (0.3) | ||
Operating expense | Cash flows, operating expenses | Foreign exchange contract | ||||
Derivatives [Line Items] | ||||
Gain on interest rate swap | (2.1) | (0.1) | ||
Other income (expense) | Net Investment Hedging | ||||
Derivatives [Line Items] | ||||
Gain (loss) recognized in net income, excluded component | $ (1.1) | |||
Euro | Foreign exchange contract | Designated as hedging instrument | ||||
Derivatives [Line Items] | ||||
Derivative, Notional Amount | 1,854.8 | 1,495.5 | ||
Swiss franc | Foreign exchange contract | Designated as hedging instrument | ||||
Derivatives [Line Items] | ||||
Derivative, Notional Amount | 124.3 | 162.8 | ||
Japan, Yen | Foreign exchange contract | Designated as hedging instrument | ||||
Derivatives [Line Items] | ||||
Derivative, Notional Amount | 43.3 | 57.2 | ||
Canadian dollar | Foreign exchange contract | Designated as hedging instrument | ||||
Derivatives [Line Items] | ||||
Derivative, Notional Amount | $ 248.2 | $ 0 | ||
Samsung Bioepis | ||||
Derivatives [Line Items] | ||||
Equity, ownership interest | 49.90% | 49.90% | ||
Percentage of stake in entity | 5% | |||
Short-term derivative | ||||
Derivatives [Line Items] | ||||
Range of durations of foreign currency forward contracts | 12 months | |||
Gain/Loss on fair value of foreign currency forward contracts | $ 30 |
Property, Plant and Equipment (
Property, Plant and Equipment (Details) $ in Millions | 3 Months Ended | ||
Mar. 31, 2023 USD ($) ft² | Mar. 31, 2022 USD ($) | Dec. 31, 2022 USD ($) | |
Property, Plant and Equipment [Line Items] | |||
Accumulated depreciation | $ | $ 2,218.2 | $ 2,165.7 | |
Depreciation | $ | $ 62.1 | $ 76.3 | |
Biologics Manufacturing | |||
Property, Plant and Equipment [Line Items] | |||
Number of square feet | ft² | 393,000 | ||
Warehouse, Utilities and Support Space | |||
Property, Plant and Equipment [Line Items] | |||
Number of square feet | ft² | 290,000 | ||
Administrative Space | |||
Property, Plant and Equipment [Line Items] | |||
Number of square feet | ft² | 51,000 | ||
Solothurn, Switzerland | |||
Property, Plant and Equipment [Line Items] | |||
Construction in progress | $ | $ 721.2 | $ 711.1 |
Share Repurchases (Details)
Share Repurchases (Details) - 2020 Share Repurchase Program - USD ($) | Mar. 31, 2023 | Oct. 31, 2020 |
Class of Stock [Line Items] | ||
Stock Repurchase Program, Authorized Amount | $ 5,000,000,000 | |
Amount remaining under 2019 Share Repurchase Program | $ 2,100,000,000 |
Accumulated Other Comprehensi_2
Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||
Accumulated other comprehensive income (loss), net of tax beginning balance | $ (164.9) | $ (106.7) |
Balance, January 1, 2018 | (172) | (115.2) |
Other comprehensive income (loss), before reclassifications, net of tax | 7.6 | 8.4 |
Amounts reclassified from accumulated other comprehensive income, net of tax | (14.7) | (16.9) |
Other comprehensive income (loss), net of tax | (7.1) | (8.5) |
Accumulated other comprehensive income (loss), net of tax ending balance | (172) | (115.2) |
Other comprehensive income (loss), net of tax | (7.1) | (8.5) |
Unrealized gains (losses) on securities available for sale | ||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||
Accumulated other comprehensive income (loss), net of tax beginning balance | (15.7) | (2.2) |
Balance, January 1, 2018 | (10) | (11.9) |
Other comprehensive income (loss), before reclassifications, net of tax | 5.3 | (10.2) |
Amounts reclassified from accumulated other comprehensive income, net of tax | 0.4 | 0.5 |
Other comprehensive income (loss), net of tax | 5.7 | (9.7) |
Accumulated other comprehensive income (loss), net of tax ending balance | (10) | (11.9) |
Unrealized gains (losses) on cash flow hedges | ||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||
Accumulated other comprehensive income (loss), net of tax beginning balance | 15.1 | 53.8 |
Balance, January 1, 2018 | (20.3) | 69.7 |
Other comprehensive income (loss), before reclassifications, net of tax | (20.3) | 34.4 |
Amounts reclassified from accumulated other comprehensive income, net of tax | (15.1) | (18.5) |
Other comprehensive income (loss), net of tax | (35.4) | 15.9 |
Accumulated other comprehensive income (loss), net of tax ending balance | (20.3) | 69.7 |
Gains (losses) on net investment hedge | ||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||
Accumulated other comprehensive income (loss), net of tax beginning balance | 25.5 | |
Balance, January 1, 2018 | 31.7 | |
Other comprehensive income (loss), before reclassifications, net of tax | 5.1 | |
Amounts reclassified from accumulated other comprehensive income, net of tax | 1.1 | |
Other comprehensive income (loss), net of tax | 6.2 | |
Accumulated other comprehensive income (loss), net of tax ending balance | 31.7 | |
Unfunded status of postretirement benefit plans | ||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||
Accumulated other comprehensive income (loss), net of tax beginning balance | (1.1) | (44.8) |
Balance, January 1, 2018 | (0.6) | (43.9) |
Other comprehensive income (loss), before reclassifications, net of tax | 0.5 | 0.9 |
Amounts reclassified from accumulated other comprehensive income, net of tax | 0 | 0 |
Other comprehensive income (loss), net of tax | 0.5 | 0.9 |
Accumulated other comprehensive income (loss), net of tax ending balance | (0.6) | (43.9) |
Currency translation adjustments | ||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||
Accumulated other comprehensive income (loss), net of tax beginning balance | (163.2) | (139) |
Balance, January 1, 2018 | (141.1) | (160.8) |
Other comprehensive income (loss), before reclassifications, net of tax | 22.1 | (21.8) |
Amounts reclassified from accumulated other comprehensive income, net of tax | 0 | 0 |
Other comprehensive income (loss), net of tax | 22.1 | (21.8) |
Accumulated other comprehensive income (loss), net of tax ending balance | $ (141.1) | $ (160.8) |
Reclassification out of Accumul
Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] | ||
Other (income) expense | $ (69.4) | $ (263.3) |
Income Tax Expense (Benefit) | 50.7 | 125.6 |
Product revenues | 2,463 | 2,531.8 |
Net income attributable to Biogen Inc. | $ 387.9 | $ 303.8 |
Samsung Bioepis | ||
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] | ||
Equity, ownership interest | 49.90% | 49.90% |
Reclassification out of Accumulated Other Comprehensive Income | ||
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] | ||
Net income attributable to Biogen Inc. | $ 14.7 | $ 16.9 |
Unrealized gains (losses) on securities available for sale | Reclassification out of Accumulated Other Comprehensive Income | ||
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] | ||
Other (income) expense | (0.5) | (0.6) |
Income Tax Expense (Benefit) | 0.1 | 0.1 |
Unrealized gains (losses) on cash flow hedges | Reclassification out of Accumulated Other Comprehensive Income | ||
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] | ||
Other (income) expense | (0.1) | (0.1) |
Income Tax Expense (Benefit) | (1.9) | (2) |
Product revenues | 17.6 | 20.9 |
Operating Expenses | (0.5) | (0.3) |
Gains (losses) on net investment hedge | Reclassification out of Accumulated Other Comprehensive Income | ||
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] | ||
Other (income) expense | $ 0 | $ (1.1) |
Earnings per Share (Details)
Earnings per Share (Details) - USD ($) shares in Thousands, $ in Millions | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Numerator: | ||
Net income attributable to Biogen Inc. | $ 387.9 | $ 303.8 |
Weighted-average shares used in calculating: | ||
Weighted average number of common shares outstanding | 144,400 | 147,100 |
Effect of dilutive securities: | ||
Dilutive potential common shares | 800 | 500 |
Shares used in calculating diluted earnings per share | 145,200 | 147,600 |
Time-vested restricted stock units | ||
Effect of dilutive securities: | ||
Stock units | 600 | 300 |
Market stock units | ||
Effect of dilutive securities: | ||
Stock units | 100 | 100 |
Performance stock units settled in stock | ||
Effect of dilutive securities: | ||
Stock units | 100 | 100 |
Share-Based Payments (Details)
Share-Based Payments (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Share-based Compensation Expense included in consolidated statements of income | ||
Share-based compensation expense | $ (78.9) | $ (70.4) |
Subtotal | 81.4 | 71.8 |
Capitalized share-based compensation costs | (3.3) | (2.8) |
Share-based compensation expense included in total costs and expenses | 78.1 | 69 |
Income tax effect | (14.7) | (12.8) |
Research and development | ||
Share-based Compensation Expense included in consolidated statements of income | ||
Share-based compensation expense | 31.3 | 25.7 |
Selling, general and administrative | ||
Share-based Compensation Expense included in consolidated statements of income | ||
Share-based compensation expense | 50.1 | 46.1 |
Total share-based compensation expense, net of tax | ||
Share-based Compensation Expense included in consolidated statements of income | ||
Share-based compensation expense | $ 63.4 | $ 56.2 |
Share-Based Payments (Details 1
Share-Based Payments (Details 1) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Summary of share based compensation expense associated with different programs [Abstract] | ||
Share-based compensation expense | $ (78.9) | $ (70.4) |
Subtotal | 81.4 | 71.8 |
Capitalized share-based compensation costs | (3.3) | (2.8) |
Share-based compensation expense included in total costs and expenses | 78.1 | 69 |
Market stock units | ||
Summary of share based compensation expense associated with different programs [Abstract] | ||
Share-based compensation expense | 2.2 | 5.9 |
Time-vested restricted stock units | ||
Summary of share based compensation expense associated with different programs [Abstract] | ||
Share-based compensation expense | 61.7 | 51.3 |
Performance stock units settled in stock | ||
Summary of share based compensation expense associated with different programs [Abstract] | ||
Share-based compensation expense | 9.5 | 8.3 |
Performance stock units settled in cash | ||
Summary of share based compensation expense associated with different programs [Abstract] | ||
Share-based compensation expense | 2.5 | 1.4 |
Employee stock purchase plan | ||
Summary of share based compensation expense associated with different programs [Abstract] | ||
Share-based compensation expense | 4.7 | 4.9 |
Options | Nightstar | ||
Summary of share based compensation expense associated with different programs [Abstract] | ||
Fair value of post-combination equity compensation | $ 0.8 | $ 0 |
Income Taxes (Details Textual)
Income Taxes (Details Textual) $ in Millions | Mar. 31, 2023 USD ($) |
Income Tax Contingency [Line Items] | |
Deferred tax assets, unrecognized tax benefit | $ 85 |
Decrease in unrecognized tax benefits is reasonably possible | 500 |
ADUHELM | |
Income Tax Contingency [Line Items] | |
Decrease in unrecognized tax benefits is reasonably possible | $ 450 |
Income Taxes (Details)
Income Taxes (Details) | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Reconciliation between the U.S. federal statutory tax rate and effective tax rate | ||
Statutory rate | 21% | 21% |
State taxes | 1.30% | (0.40%) |
Taxes on foreign earnings | (5.60%) | (10.80%) |
Credits and net operating loss utilization | (6.60%) | (2.50%) |
Purchased intangible assets | 0.40% | 0.60% |
GILTI | 0.50% | 0.30% |
Neurimmune tax impacts | 0 | 0.242 |
Other | 0.60% | 3.80% |
Effective tax rate | 11.60% | 36.20% |
Other Consolidated Financial _3
Other Consolidated Financial Statement Detail (Details) - USD ($) $ in Millions | 3 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2022 | |
Other Income (Expense), Net | |||
Interest income | $ (80.9) | $ (2.9) | |
Interest expense | 62.5 | 66.1 | |
(Gains) losses on investments, net | 77.7 | 191.1 | |
Foreign exchange (gains) losses, net | 10.7 | 8.3 | |
Other, net | (0.6) | 0.7 | |
Other (income) expense | 69.4 | 263.3 | |
Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract] | |||
Net (gains) losses recognized on equity securities | 78.1 | 190.7 | |
Less: Net (gains) losses realized on equity securities | 1.6 | (0.2) | |
Net unrealized (gains) losses recognized on equity securities | 76.5 | 190.9 | |
Accrued Expenses and Other | |||
Revenue-related reserves for discounts and allowances | 1,045 | $ 1,035 | |
Collaboration expense | 187.2 | 395.6 | |
Royalties and licensing fees | 183.9 | 209.4 | |
Collaboration expense | 265.5 | 277.9 | |
Other | 744.4 | 746.9 | |
Total accrued expense and other | 2,288.2 | 2,521.4 | |
Ionis, Sangamo, Denali and Sage | |||
Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract] | |||
Net unrealized (gains) losses recognized on equity securities | 100 | $ 205.5 | |
Component of accrued expenses and other | |||
Accrued Expenses and Other | |||
Revenue-related reserves for discounts and allowances | $ 907.2 | $ 891.6 |
Other Consolidated Financial _4
Other Consolidated Financial Statement (Details Textual) - USD ($) $ in Millions | 3 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2022 | |
Net gains recognized on the increase in fair value of equity securities | $ 76.5 | $ 190.9 | |
Net gains (losses) realized during the period on equity securities | 1.6 | (0.2) | |
Other long-term liabilities | 935.5 | $ 944.2 | |
Accrued income taxes | 552.5 | $ 541.7 | |
Ionis, Sangamo, Denali and Sage | |||
Net gains recognized on the increase in fair value of equity securities | $ 100 | $ 205.5 |
Collaborative and Other Relat_3
Collaborative and Other Relationships - OCREVUS (Details) - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended |
Mar. 31, 2017 | Mar. 31, 2023 | |
OCREVUS | ||
Collaborative arrangements and non-collaborative arrangement transactions | ||
Royalty operating profit threshold for highest royalty rate percentage | $ 900 | |
Reduction in royalty rate | 50% | |
Collaboration agreement term | 11 years | |
OCREVUS | Foreign Tax Authority | ||
Collaborative arrangements and non-collaborative arrangement transactions | ||
Royalty percentage to be received | 3% | |
OCREVUS | Minimum | ||
Collaborative arrangements and non-collaborative arrangement transactions | ||
Royalty percentage to be received | 13.50% | |
OCREVUS | Maximum | ||
Collaborative arrangements and non-collaborative arrangement transactions | ||
Royalty percentage to be received | 24% | |
Mosunetuzumab | ||
Collaborative arrangements and non-collaborative arrangement transactions | ||
Percentage of future development costs | 30% |
Collaborative and Other Relat_4
Collaborative and Other Relationships - Profit Sharing (Details) $ in Millions | 3 Months Ended |
Mar. 31, 2023 USD ($) | |
RITUXAN | |
Collaborative arrangements and non-collaborative arrangement transactions | |
Percentage of co promotion operating profits first fifty million | 30% |
Until Second GAZYVA Threshold Date | 37.50% |
After Second GAZYVA Threshold Date | 35% |
Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Four | 30% |
GAZYVA | |
Collaborative arrangements and non-collaborative arrangement transactions | |
Co-promotion operating profit threshold for Rituxan in US and Canada to determine share of co promotion operating profit prior to amendment | $ 50 |
Until Second GAZYVA Threshold Date | 37.50% |
After Second GAZYVA Threshold Date | 35% |
Limit of gross sale of GAZYVA to be achieved in preceding 12 months under option one | $ 500 |
Limit of gross sale of GAZYVA to be achieved in any 12 months under option one | 150 |
Sales trigger gross sales threshold | $ 350 |
Collaborative and Other Relat_5
Collaborative and Other Relationships - Eisai (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Collaborative arrangements and non-collaborative arrangement transactions | ||
Product revenues | $ 2,463 | $ 2,531.8 |
LEQEMBI Collaboration | ||
Collaborative arrangements and non-collaborative arrangement transactions | ||
Product revenues | (18.9) | $ 0 |
Payable Due To Termination Agreement | $ 31 |
Collaborative and Other Relat_6
Collaborative and Other Relationships - Summary of Activity Related to BAN2401 and Elenbecestat Collaboration (Details) - Eisai - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
E2609 and BAN2401 | ||
Collaborative arrangements and non-collaborative arrangement transactions | ||
Total development expense incurred by the collaboration related to the advancement of LEQEMBI | $ 107.9 | $ 77 |
Expense reflected within statements of income | 54 | 38.5 |
Selling, general and administrative | E2609 and BAN2401 | ||
Collaborative arrangements and non-collaborative arrangement transactions | ||
Expense reflected within statements of income | 5.3 | 8 |
Expense incurred by the collaboration | $ 10.5 | 15.9 |
Selling, general and administrative | ADUHELM | ||
Collaborative arrangements and non-collaborative arrangement transactions | ||
Expense reflected within statements of income | 50.9 | |
Expense incurred by the collaboration | $ 95 |
Collaborative and Other Relat_7
Collaborative and Other Relationships - ADUHELM Collaboration Agreement (Details) - USD ($) $ in Millions | 3 Months Ended | ||
Mar. 31, 2023 | Dec. 31, 2022 | Mar. 31, 2022 | |
Collaborative arrangements and non-collaborative arrangement transactions | |||
Percentage of future development costs related to Eisai | 45% | ||
Excess and obsolescence charges related to inventory | $ 17.4 | $ 281.5 | |
ADUHELM | |||
Collaborative arrangements and non-collaborative arrangement transactions | |||
Excess and obsolescence charges related to inventory | $ 275 | 275 | |
ADUHELM | Maximum | |||
Collaborative arrangements and non-collaborative arrangement transactions | |||
Research and development expense asset acquired | 335 | ||
ADUHELM | Cost of Sales | |||
Collaborative arrangements and non-collaborative arrangement transactions | |||
Excess and obsolescence charges related to inventory | $ 45 | ||
Eisai | |||
Collaborative arrangements and non-collaborative arrangement transactions | |||
Percentage of future development costs related to Eisai | 45% | ||
Amounts receivable | 72.6 | 88 | |
Amounts payable | 137.8 | $ 81.2 | |
Eisai | Collaboration profit sharing | |||
Collaborative arrangements and non-collaborative arrangement transactions | |||
Recognized net reductions to operating expense | $ 181.7 | ||
Eisai | ADUHELM | Inventory, Idle Capacity Charges And Contractual Commitments | |||
Collaborative arrangements and non-collaborative arrangement transactions | |||
Recognized net reductions to operating expense | $ 160 |
Collaborative and Other Relat_8
Collaborative and Other Relationships - Summary of Activity Related to ADUHELM Collaboration (Details) - Eisai - ADUHELM $ in Millions | 3 Months Ended |
Mar. 31, 2022 USD ($) | |
Research and development | |
Collaborative arrangements and non-collaborative arrangement transactions | |
Expense incurred by the collaboration | $ 44.2 |
Expense reflected within statements of income | 24.3 |
Selling, general and administrative | |
Collaborative arrangements and non-collaborative arrangement transactions | |
Expense incurred by the collaboration | 95 |
Expense reflected within statements of income | $ 50.9 |
Collaborative and Other Relat_9
Collaborative and Other Relationships - Summary of Activity Related to the UCB Collaboration (Details) - Research and development - UCB Pharma S.A. - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Collaborative arrangements and non-collaborative arrangement transactions | ||
Expense incurred by the collaboration | $ 18.3 | $ 17.6 |
Expense reflected within statements of income | $ 9.2 | $ 8.8 |
Collaborative and Other Rela_10
Collaborative and Other Relationships - Summary of Activity Related to Sage Therapeutics (Details) - Sage Therapeutics - USD ($) $ in Millions | 3 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2023 | |
Forecast | |||
Collaborative arrangements and non-collaborative arrangement transactions | |||
Potential future milestone payments commitment to third party | $ 225 | ||
Research and development | |||
Collaborative arrangements and non-collaborative arrangement transactions | |||
Expense incurred by the collaboration | $ 34.8 | $ 38.7 | |
Expense reflected within statements of income | 17.4 | 19.4 | |
Selling, general and administrative | |||
Collaborative arrangements and non-collaborative arrangement transactions | |||
Expense incurred by the collaboration | 38.2 | 18.4 | |
Expense reflected within statements of income | $ 19.1 | $ 9.2 |
Collaborative and Other Rela_11
Collaborative and Other Relationships - Summary of Activity Related To Denali Therapeutics (Details) - Research and development - Denali Therapeutics - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Collaborative arrangements and non-collaborative arrangement transactions | ||
Expense incurred by the collaboration | $ 16.6 | $ 14.9 |
Expense reflected within statements of income | $ 10 | $ 8.9 |
Collaborative and Other Rela_12
Collaborative and Other Relationships - Summary of Activity Related to Sangamo Therapeutics (Details) - Sangamo Therapeutics, Inc. Agreement - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Collaborative arrangements and non-collaborative arrangement transactions | ||
Term of collaboration agreement | 5 years | |
Research and development | ||
Collaborative arrangements and non-collaborative arrangement transactions | ||
Expense incurred by the collaboration | $ 5.1 | $ 8.3 |
Expense reflected within statements of income | $ 2.3 | $ 5.5 |
Collaborative and Other Rela_13
Collaborative and Other Relationships - Other Arrangements (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Collaborative arrangements and non-collaborative arrangement transactions | ||
Research and development | $ 570.6 | $ 551.7 |
Other research and discovery | ||
Collaborative arrangements and non-collaborative arrangement transactions | ||
Research and development | $ 0.2 | $ 19.5 |
Collaborative and Other Rela_14
Collaborative and Other Relationships - Samsung Bioepis (Details) $ in Millions | 1 Months Ended | 3 Months Ended | ||
Dec. 31, 2019 product | Mar. 31, 2023 USD ($) | Mar. 31, 2022 USD ($) | Dec. 31, 2022 USD ($) | |
Collaborative arrangements and non-collaborative arrangement transactions | ||||
Collaboration profit sharing/(loss reimbursement) | $ 57.1 | $ (117.3) | ||
Samsung Bioepis | ||||
Collaborative arrangements and non-collaborative arrangement transactions | ||||
Collaboration profit sharing/(loss reimbursement) | $ 57.1 | $ 64.4 | ||
Samsung Bioepis | ||||
Collaborative arrangements and non-collaborative arrangement transactions | ||||
Contingent Commercialized Rights, Number Of Products | product | 2 | |||
Expected profit share percentage | 45% | 50% | ||
Estimated additional payments upon achievement of development and commercial milestones | $ 180 | |||
Collaboration agreement term | 5 years | |||
Option exercise fee | $ 60 | |||
Due from Related Parties | 6.3 | $ 2 | ||
Due to Related Parties | $ 32.2 | $ 40.5 |
Investments in Variable Inter_2
Investments in Variable Interest Entities (Details) - USD ($) $ in Millions | 3 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2022 | |
Variable Interest Entity [Line Items] | |||
(Gain) loss on equity method investments | $ 0 | $ (3.3) | |
Percentage of future development costs related to Eisai | 45% | ||
Deferred tax assets, unrecognized tax benefit | $ 85 | ||
Investment in biotechnology companies that are determined to be unconsolidated variable interest entities | $ 28 | $ 27.8 | |
Neurimmune | |||
Variable Interest Entity [Line Items] | |||
Collaboration agreement term | 12 years | ||
Research and development costs, percentage | 100% | ||
Eisai | |||
Variable Interest Entity [Line Items] | |||
Percentage of future development costs related to Eisai | 45% |
Litigation (Details)
Litigation (Details) $ in Millions | Dec. 31, 2021 USD ($) |
Loss Contingency, Information about Litigation Matters [Abstract] | |
Loss Contingency, Estimate of Possible Loss | $ 200 |